|
G |
ARHGEF26 |
Rho guanine nucleotide exchange factor 26 |
increases expression |
EXP |
Amphotericin B results in increased expression of ARHGEF26 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 3:154,121,003...154,257,825
Ensembl chr 3:154,121,003...154,257,827
|
|
G |
ARNT |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
EXP |
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer] |
CTD |
PMID:16189267 |
|
NCBI chr 1:150,809,713...150,876,599
Ensembl chr 1:150,809,713...150,876,708
|
|
G |
ATG3 |
autophagy related 3 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of ATG3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 3:112,532,510...112,561,962
Ensembl chr 3:112,532,510...112,562,046
|
|
G |
CASP3 |
caspase 3 |
increases expression |
ISO |
Amphotericin B results in increased expression of CASP3 protein |
CTD |
PMID:23988732 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CAT |
catalase |
decreases expression |
ISO |
Amphotericin B results in decreased expression of CAT mRNA |
CTD |
PMID:20623750 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCR2 |
C-C motif chemokine receptor 2 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of CCR2 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 3:46,354,111...46,360,940
Ensembl chr 3:46,353,864...46,360,940
|
|
G |
CLU |
clusterin |
affects expression |
ISO |
Amphotericin B affects the expression of CLU mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 8:27,596,917...27,614,700
Ensembl chr 8:27,596,917...27,614,700
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
increases expression multiple interactions |
EXP |
Amphotericin B results in increased expression of CXCL8 mRNA [Amphotericin B co-treated with lipopolysaccharide, E. coli O26-B6] results in increased expression of CXCL8 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
EDNRB |
endothelin receptor type B |
increases expression |
EXP |
Amphotericin B results in increased expression of EDNRB mRNA |
CTD |
PMID:20849824 |
|
NCBI chr13:77,895,481...77,975,527
Ensembl chr13:77,895,481...77,975,529
|
|
G |
ENO1 |
enolase 1 |
multiple interactions |
EXP |
Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of ENO1 mRNA]; Amphotericin B results in increased expression of and results in increased secretion of ENO1 protein |
CTD |
PMID:16189267 PMID:26259607 |
|
NCBI chr 1:8,861,000...8,878,686
Ensembl chr 1:8,861,000...8,879,190
|
|
G |
EP300 |
E1A binding protein p300 |
multiple interactions |
EXP |
Amphotericin B inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]] |
CTD |
PMID:16189267 |
|
NCBI chr22:41,092,592...41,180,077
Ensembl chr22:41,092,592...41,180,077
|
|
G |
EPO |
erythropoietin |
multiple interactions decreases expression |
EXP ISO |
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer]; Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA] Amphotericin B results in decreased expression of EPO protein |
CTD |
PMID:697352 PMID:2299214 PMID:16189267 |
|
NCBI chr 7:100,720,468...100,723,700
Ensembl chr 7:100,720,468...100,723,700
|
|
G |
GLOD4 |
glyoxalase domain containing 4 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of GLOD4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr17:759,330...785,895
Ensembl chr17:757,097...782,294
|
|
G |
GPR20 |
G protein-coupled receptor 20 |
increases expression |
EXP |
Amphotericin B results in increased expression of GPR20 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 8:141,356,470...141,367,286
Ensembl chr 8:141,356,470...141,367,286
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
decreases expression multiple interactions |
ISO EXP |
Amphotericin B results in decreased expression of GSTP1 mRNA Amphotericin B inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:20623750 PMID:23769903 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
|
|
G |
GSTT1 |
glutathione S-transferase theta 1 |
decreases expression |
ISO |
Amphotericin B results in decreased expression of GSTT1 mRNA |
CTD |
PMID:20623750 |
|
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases activity |
EXP |
Amphotericin B inhibits the reaction [[HIF1A protein binds to ARNT protein] which binds to EPO enhancer]; Amphotericin B inhibits the reaction [Oxygen deficiency promotes the reaction [HIF1A protein binds to EP300 protein]]; Amphotericin B promotes the reaction [HIF1AN protein binds to and results in increased hydroxylation of and results in decreased activity of HIF1A protein] Amphotericin B results in decreased activity of HIF1A protein |
CTD |
PMID:16189267 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HIF1AN |
hypoxia inducible factor 1 subunit alpha inhibitor |
multiple interactions |
EXP |
Amphotericin B promotes the reaction [HIF1AN protein binds to and results in increased hydroxylation of and results in decreased activity of HIF1A protein] |
CTD |
PMID:16189267 |
|
NCBI chr10:100,535,943...100,559,998
Ensembl chr10:100,529,072...100,559,998
|
|
G |
HLA-F |
major histocompatibility complex, class I, F |
increases expression |
EXP |
Amphotericin B results in increased expression of HLA-F mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 6:29,723,434...29,738,532
Ensembl chr 6:29,722,775...29,738,528
|
|
G |
HSPA8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
EXP |
Amphotericin B results in increased expression of and results in increased secretion of HSPA8 protein |
CTD |
PMID:26259607 |
|
NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230
|
|
G |
IFNG |
interferon gamma |
multiple interactions |
EXP |
[Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA; [Antimony Sodium Gluconate co-treated with Amphotericin B] results in increased expression of IFNG protein |
CTD |
PMID:17911647 PMID:29594315 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IFNGR1 |
interferon gamma receptor 1 |
increases expression |
EXP |
Amphotericin B results in increased expression of IFNGR1 |
CTD |
PMID:12803856 |
|
NCBI chr 6:137,197,484...137,219,385
Ensembl chr 6:137,197,483...137,219,449
|
|
G |
IGFBP5 |
insulin like growth factor binding protein 5 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of IGFBP5 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 2:216,672,105...216,695,549
Ensembl chr 2:216,672,105...216,695,549
|
|
G |
IL10 |
interleukin 10 |
multiple interactions |
EXP |
[Antimony Sodium Gluconate co-treated with Amphotericin B] results in decreased expression of IL10 protein |
CTD |
PMID:17911647 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL1B |
interleukin 1 beta |
increases expression |
EXP |
Amphotericin B results in increased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL2 |
interleukin 2 |
multiple interactions |
EXP |
[Amphotericin B co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 4:122,451,470...122,456,725
Ensembl chr 4:122,451,470...122,456,725
|
|
G |
KCNQ4 |
potassium voltage-gated channel subfamily Q member 4 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of KCNQ4 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:40,783,787...40,840,452
Ensembl chr 1:40,783,787...40,840,452
|
|
G |
LSG1 |
large 60S subunit nuclear export GTPase 1 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of LSG1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 3:194,640,791...194,672,191
Ensembl chr 3:194,640,791...194,672,463
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
increases expression |
ISO |
Amphotericin B results in increased expression of MAP1LC3B protein |
CTD |
PMID:23988732 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
NPRL2 |
NPR2 like, GATOR1 complex subunit |
decreases expression |
EXP |
Amphotericin B results in decreased expression of NPRL2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 3:50,347,330...50,350,775
Ensembl chr 3:50,347,330...50,350,826
|
|
G |
NT5C2 |
5'-nucleotidase, cytosolic II |
increases expression |
EXP |
Amphotericin B results in increased expression of NT5C2 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr10:103,088,017...103,193,272
Ensembl chr10:103,087,185...103,277,605
|
|
G |
PAIP1 |
poly(A) binding protein interacting protein 1 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of PAIP1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 5:43,526,267...43,557,411
Ensembl chr 5:43,526,267...43,557,758
|
|
G |
PARD3 |
par-3 family cell polarity regulator |
decreases expression |
EXP |
Amphotericin B results in decreased expression of PARD3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr10:34,109,561...34,815,296
Ensembl chr10:34,109,560...34,815,325
|
|
G |
PGK1 |
phosphoglycerate kinase 1 |
multiple interactions |
EXP |
Amphotericin B inhibits the reaction [Oxygen deficiency results in increased expression of PGK1 mRNA] |
CTD |
PMID:16189267 |
|
NCBI chr X:78,104,248...78,129,295
Ensembl chr X:77,910,739...78,129,295
|
|
G |
POLM |
DNA polymerase mu |
increases expression |
EXP |
Amphotericin B results in increased expression of POLM mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 7:44,072,062...44,082,530
Ensembl chr 7:44,072,062...44,082,530
|
|
G |
RUNX3 |
RUNX family transcription factor 3 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of RUNX3 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr 1:24,899,511...24,965,138
Ensembl chr 1:24,899,511...24,965,121
|
|
G |
SLIT1 |
slit guidance ligand 1 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of SLIT1 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr10:96,998,038...97,185,959
Ensembl chr10:96,998,038...97,185,959
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
affects expression |
ISO |
Amphotericin B affects the expression of SPP1 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
multiple interactions |
EXP |
[Antimony Sodium Gluconate co-treated with Amphotericin B] results in decreased expression of TGFB1 protein |
CTD |
PMID:17911647 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
TMPRSS2 |
transmembrane serine protease 2 |
increases expression |
EXP |
Amphotericin B results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116
|
|
G |
TNF |
tumor necrosis factor |
increases expression |
ISO |
Amphotericin B results in increased expression of TNF mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
UGT1A9 |
UDP glucuronosyltransferase family 1 member A9 |
affects expression |
ISO |
Amphotericin B affects the expression of UGT1A9 mRNA |
CTD |
PMID:20623750 |
|
NCBI chr 2:233,671,898...233,773,300
Ensembl chr 2:233,671,898...233,773,300
|
|
G |
USP36 |
ubiquitin specific peptidase 36 |
increases expression |
EXP |
Amphotericin B results in increased expression of USP36 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr17:78,787,381...78,841,439
Ensembl chr17:78,787,381...78,841,441
|
|
G |
ZNF671 |
zinc finger protein 671 |
decreases expression |
EXP |
Amphotericin B results in decreased expression of ZNF671 mRNA |
CTD |
PMID:20849824 |
|
NCBI chr19:57,719,751...57,727,624
Ensembl chr19:57,719,751...57,727,624
|
|
|
G |
HAVCR1 |
hepatitis A virus cellular receptor 1 |
increases expression |
ISO |
methylamphotericin B results in increased expression of HAVCR1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 5:157,029,413...157,069,407
Ensembl chr 5:157,029,413...157,059,119
|
|
G |
LCN2 |
lipocalin 2 |
increases expression |
ISO |
methylamphotericin B results in increased expression of LCN2 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 9:128,149,453...128,153,453
Ensembl chr 9:128,149,071...128,153,453
|
|
G |
SPP1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
methylamphotericin B results in increased expression of SPP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr 4:87,975,714...87,983,411
Ensembl chr 4:87,975,667...87,983,532
|
|
G |
TIMP1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
methylamphotericin B results in increased expression of TIMP1 mRNA |
CTD |
PMID:22863853 |
|
NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789
|
|
|
G |
AGO3 |
argonaute RISC catalytic component 3 |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of AGO3 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 1:35,930,718...36,072,500
Ensembl chr 1:35,930,718...36,072,500
|
|
G |
AKAP9 |
A-kinase anchoring protein 9 |
multiple interactions |
EXP |
Emetine inhibits the reaction [sodium arsenite affects the localization of AKAP9 protein] |
CTD |
PMID:19073175 |
|
NCBI chr 7:91,940,862...92,110,673
Ensembl chr 7:91,940,840...92,110,673
|
|
G |
AR |
androgen receptor |
multiple interactions |
EXP |
Emetine binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:67,544,021...67,730,619
Ensembl chr X:67,544,021...67,730,619
|
|
G |
BRCA1 |
BRCA1 DNA repair associated |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of BRCA1 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr17:43,044,295...43,125,364
Ensembl chr17:43,044,295...43,170,245
|
|
G |
CAPRIN1 |
cell cycle associated protein 1 |
multiple interactions |
EXP |
Emetine inhibits the reaction [sodium arsenite affects the localization of CAPRIN1 protein] |
CTD |
PMID:19073175 |
|
NCBI chr11:34,051,731...34,102,610
Ensembl chr11:34,051,731...34,102,610
|
|
G |
CASP3 |
caspase 3 |
increases activity |
ISO |
Emetine results in increased activity of CASP3 protein |
CTD |
PMID:14502240 |
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CASP9 |
caspase 9 |
increases activity |
ISO |
Emetine results in increased activity of CASP9 protein |
CTD |
PMID:14502240 |
|
NCBI chr 1:15,491,401...15,524,912
Ensembl chr 1:15,490,832...15,526,534
|
|
G |
CCAR1 |
cell division cycle and apoptosis regulator 1 |
multiple interactions |
EXP |
Emetine inhibits the reaction [sodium arsenite affects the localization of CCAR1 protein] |
CTD |
PMID:19073175 |
|
NCBI chr10:68,721,239...68,792,377
Ensembl chr10:68,721,012...68,792,377
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
decreases expression |
EXP |
Emetine results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCL3 |
C-C motif chemokine ligand 3 |
decreases expression |
EXP |
Emetine results in decreased expression of CCL3 protein |
CTD |
PMID:20116850 |
|
NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
|
|
G |
CCL4 |
C-C motif chemokine ligand 4 |
decreases expression |
EXP |
Emetine results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr17:36,103,827...36,105,614
Ensembl chr17:36,103,827...36,105,621
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
decreases expression |
EXP |
Emetine results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CREB1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of CREB1 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 2:207,529,962...207,605,988
Ensembl chr 2:207,529,737...207,605,988
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
decreases expression |
EXP |
Emetine results in decreased expression of CXCL8 protein |
CTD |
PMID:20116850 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
ESR1 |
estrogen receptor 1 |
multiple interactions |
EXP |
Emetine binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:25752796 |
|
NCBI chr 6:151,656,672...152,129,619
Ensembl chr 6:151,656,691...152,129,619
|
|
G |
ESR2 |
estrogen receptor 2 |
multiple interactions |
EXP |
Emetine binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:25752796 |
|
NCBI chr14:64,226,707...64,338,613
Ensembl chr14:64,084,232...64,338,112
|
|
G |
IL6R |
interleukin 6 receptor |
decreases expression |
EXP |
Emetine results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 1:154,405,343...154,469,450
Ensembl chr 1:154,405,193...154,469,450
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK1 protein] MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:15772366 PMID:26332055 |
|
NCBI chr22:21,759,657...21,867,680
Ensembl chr22:21,759,657...21,867,680
|
|
G |
MAPK14 |
mitogen-activated protein kinase 14 |
multiple interactions |
EXP |
Emetine results in increased phosphorylation of and results in increased activity of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP2 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP9 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK1 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:16364386 PMID:26332055 |
|
NCBI chr 6:36,027,808...36,124,214
Ensembl chr 6:36,027,677...36,111,236
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
increases phosphorylation decreases phosphorylation multiple interactions |
ISO EXP |
Emetine results in increased phosphorylation of MAPK3 protein Emetine results in decreased phosphorylation of MAPK3 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK3 protein] 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15772366 PMID:26332055 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:15772366 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions increases phosphorylation |
ISO |
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:15772366 |
|
NCBI chr 5:180,233,143...180,292,083
Ensembl chr 5:180,233,143...180,292,099
|
|
G |
MAPT |
microtubule associated protein tau |
decreases expression |
EXP |
Emetine results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr17:45,894,554...46,028,334
Ensembl chr17:45,894,527...46,028,334
|
|
G |
MMP2 |
matrix metallopeptidase 2 |
decreases activity multiple interactions decreases expression |
EXP |
Emetine results in decreased activity of MMP2 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP2 protein] Emetine results in decreased expression of MMP2 mRNA |
CTD |
PMID:26332055 |
|
NCBI chr16:55,478,830...55,506,691
Ensembl chr16:55,389,700...55,506,691
|
|
G |
MMP9 |
matrix metallopeptidase 9 |
decreases activity multiple interactions decreases expression |
EXP |
Emetine results in decreased activity of MMP9 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP9 protein] Emetine results in decreased expression of MMP9 mRNA |
CTD |
PMID:26332055 |
|
NCBI chr20:46,008,908...46,016,561
Ensembl chr20:46,008,908...46,016,561
|
|
G |
NR1H4 |
nuclear receptor subfamily 1 group H member 4 |
multiple interactions |
EXP |
Emetine inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
increases cleavage |
EXP |
Emetine results in increased cleavage of PARP1 protein |
CTD |
PMID:21256112 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PGR |
progesterone receptor |
multiple interactions |
EXP |
Emetine binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr11:101,029,624...101,129,813
Ensembl chr11:101,029,624...101,129,813
|
|
G |
RECK |
reversion inducing cysteine rich protein with kazal motifs |
decreases expression |
EXP |
Emetine results in decreased expression of RECK mRNA |
CTD |
PMID:26332055 |
|
NCBI chr 9:36,036,913...36,124,455
Ensembl chr 9:36,036,913...36,124,455
|
|
G |
RICTOR |
RPTOR independent companion of MTOR complex 2 |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of RICTOR mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 5:38,937,920...39,074,399
Ensembl chr 5:38,937,920...39,074,399
|
|
G |
TARDBP |
TAR DNA binding protein |
multiple interactions |
ISO |
Emetine affects the reaction [TARDBP protein binds to TIA1 protein]; Emetine affects the reaction [TARDBP protein binds to TIAR protein] |
CTD |
PMID:19765185 |
|
NCBI chr 1:11,012,654...11,030,528
Ensembl chr 1:11,012,344...11,030,528
|
|
G |
TGFB1 |
transforming growth factor beta 1 |
decreases activity |
EXP |
Emetine results in decreased activity of TGFB1 protein |
CTD |
PMID:31652400 |
|
NCBI chr19:41,330,323...41,353,922
Ensembl chr19:41,301,587...41,353,922
|
|
G |
THRA |
thyroid hormone receptor alpha |
multiple interactions |
EXP |
Emetine binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr17:40,062,193...40,093,867
Ensembl chr17:40,058,290...40,093,867
|
|
G |
THRB |
thyroid hormone receptor beta |
multiple interactions |
EXP |
Emetine binds to and results in decreased activity of THRB protein |
CTD |
PMID:25752796 |
|
NCBI chr 3:24,117,153...24,495,708
Ensembl chr 3:24,117,153...24,495,756
|
|
G |
TIA1 |
TIA1 cytotoxic granule associated RNA binding protein |
multiple interactions |
ISO |
Emetine affects the reaction [TARDBP protein binds to TIA1 protein] |
CTD |
PMID:19765185 |
|
NCBI chr 2:70,209,444...70,248,793
Ensembl chr 2:70,209,444...70,248,660
|
|
G |
TIAL1 |
TIA1 cytotoxic granule associated RNA binding protein like 1 |
multiple interactions |
ISO |
Emetine affects the reaction [TARDBP protein binds to TIAR protein] |
CTD |
PMID:19765185 |
|
NCBI chr10:119,573,465...119,596,964
Ensembl chr10:119,571,802...119,597,029
|
|
G |
VEGFA |
vascular endothelial growth factor A |
decreases expression |
EXP |
Emetine results in decreased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr 6:43,770,209...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
XIAP |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of XIAP mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr X:123,859,708...123,913,972
Ensembl chr X:123,859,724...123,913,976
|
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
multiple interactions |
EXP |
Iodoquinol inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
|
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
ISO |
Metronidazole results in decreased expression of ABCC2 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
Metronidazole results in increased expression of ABCC3 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
|
|
G |
ABCG8 |
ATP binding cassette subfamily G member 8 |
increases expression |
ISO |
Metronidazole results in increased expression of ABCG8 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988
|
|
G |
ACACA |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of ACACA mRNA |
CTD |
PMID:34979169 |
|
NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836
|
|
G |
ACAT2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACAT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:159,762,045...159,779,112
Ensembl chr 6:159,762,045...159,779,112
|
|
G |
ACE2 |
angiotensin converting enzyme 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ACE2 protein |
CTD |
PMID:30545405 |
|
NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of ADIPOQ mRNA |
CTD |
PMID:34979169 |
|
NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
|
|
G |
AHSG |
alpha 2-HS glycoprotein |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of AHSG protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:186,613,060...186,621,318
Ensembl chr 3:186,613,060...186,621,318
|
|
G |
ALDOA |
aldolase, fructose-bisphosphate A |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOA protein |
CTD |
PMID:30545405 |
|
NCBI chr16:30,064,279...30,070,420
Ensembl chr16:30,064,164...30,070,457
|
|
G |
ALDOB |
aldolase, fructose-bisphosphate B |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ALDOB protein |
CTD |
PMID:30545405 |
|
NCBI chr 9:101,420,560...101,435,774
Ensembl chr 9:101,420,560...101,449,664
|
|
G |
ARG2 |
arginase 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ARG2 protein |
CTD |
PMID:30545405 |
|
NCBI chr14:67,619,920...67,651,708
Ensembl chr14:67,619,920...67,651,708
|
|
G |
ARPC3 |
actin related protein 2/3 complex subunit 3 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ARPC3 protein |
CTD |
PMID:30545405 |
|
NCBI chr12:110,434,823...110,450,337
Ensembl chr12:110,434,823...110,450,422
|
|
G |
ASAH1 |
N-acylsphingosine amidohydrolase 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of ASAH1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:18,055,992...18,084,961
Ensembl chr 8:18,055,992...18,084,998
|
|
G |
ATP1A1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP1A1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:116,373,244...116,404,774
Ensembl chr 1:116,372,668...116,410,261
|
|
G |
ATP2A3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP2A3 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:3,923,873...3,964,437
Ensembl chr17:3,923,870...3,964,464
|
|
G |
ATP5MF |
ATP synthase membrane subunit f |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5J2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 7:99,458,195...99,466,167
Ensembl chr 7:99,448,475...99,466,186
|
|
G |
ATP5PD |
ATP synthase peripheral stalk subunit d |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5H protein |
CTD |
PMID:30545405 |
|
NCBI chr17:75,038,863...75,046,969
Ensembl chr17:75,038,863...75,046,985
|
|
G |
ATP5PF |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ATP5J protein |
CTD |
PMID:30545405 |
|
NCBI chr21:25,724,500...25,735,653
Ensembl chr21:25,716,503...25,735,673
|
|
G |
B3GALT5 |
beta-1,3-galactosyltransferase 5 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of B3GALT5 protein |
CTD |
PMID:30545405 |
|
NCBI chr21:39,612,940...39,673,137
Ensembl chr21:39,556,442...39,673,137
|
|
G |
CLCA4 |
chloride channel accessory 4 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLCA4 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:86,547,078...86,580,754
Ensembl chr 1:86,547,078...86,580,754
|
|
G |
CLDN7 |
claudin 7 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CLDN7 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:7,259,903...7,263,213
Ensembl chr17:7,259,903...7,263,983
|
|
G |
CMBL |
carboxymethylenebutenolidase homolog |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CMBL protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:10,277,595...10,307,902
Ensembl chr 5:10,275,875...10,307,902
|
|
G |
CNDP2 |
carnosine dipeptidase 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of CNDP2 protein |
CTD |
PMID:30545405 |
|
NCBI chr18:74,496,363...74,523,454
Ensembl chr18:74,495,816...74,523,454
|
|
G |
COX5A |
cytochrome c oxidase subunit 5A |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX5A protein |
CTD |
PMID:30545405 |
|
NCBI chr15:74,919,791...74,938,073
Ensembl chr15:74,919,791...74,938,083
|
|
G |
COX6B1 |
cytochrome c oxidase subunit 6B1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX6B1 protein |
CTD |
PMID:30545405 |
|
NCBI chr19:35,648,323...35,658,782
Ensembl chr19:35,648,323...35,658,782
|
|
G |
COX7A2 |
cytochrome c oxidase subunit 7A2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of COX7A2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:75,237,675...75,250,298
Ensembl chr 6:75,237,675...75,250,323
|
|
G |
CSF2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of CSF2 protein |
CTD |
PMID:31442584 |
|
NCBI chr 5:132,073,789...132,076,170
Ensembl chr 5:132,073,789...132,076,170
|
|
G |
CTSA |
cathepsin A |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CTSA protein |
CTD |
PMID:30545405 |
|
NCBI chr20:45,891,335...45,898,820
Ensembl chr20:45,890,144...45,898,949
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions |
EXP ISO |
Metronidazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Amiodarone]; Metronidazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Tacrolimus]; Metronidazole inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] [Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of CYP3A2 mRNA |
CTD |
PMID:15855244 PMID:15869686 PMID:19299527 PMID:30545405 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
EPCAM |
epithelial cell adhesion molecule |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EPCAM protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:47,369,311...47,387,020
Ensembl chr 2:47,345,158...47,387,601
|
|
G |
EREG |
epiregulin |
increases expression |
EXP |
Metronidazole results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:74,365,145...74,388,749
Ensembl chr 4:74,365,145...74,388,749
|
|
G |
ETFA |
electron transfer flavoprotein subunit alpha |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of ETFA protein |
CTD |
PMID:30545405 |
|
NCBI chr15:76,215,353...76,311,469
Ensembl chr15:76,188,555...76,311,730
|
|
G |
EZR |
ezrin |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of EZR protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:158,765,748...158,819,368
Ensembl chr 6:158,765,741...158,819,368
|
|
G |
FASN |
fatty acid synthase |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased expression of FASN mRNA] |
CTD |
PMID:34979169 |
|
NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
|
|
G |
GFPT2 |
glutamine-fructose-6-phosphate transaminase 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GFPT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:180,300,698...180,353,336
Ensembl chr 5:180,300,698...180,353,336
|
|
G |
GIPC2 |
GIPC PDZ domain containing family member 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GIPC2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:78,044,970...78,138,444
Ensembl chr 1:77,979,542...78,138,444
|
|
G |
GNG12 |
G protein subunit gamma 12 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of GNG12 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:67,701,475...67,833,467
Ensembl chr 1:67,701,475...67,833,467
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased activity of GPT protein] |
CTD |
PMID:34979169 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GPX1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GPX1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,176...49,358,353
|
|
G |
GSTM2 |
glutathione S-transferase mu 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of GSTM2 mRNA |
CTD |
PMID:30545405 |
|
NCBI chr 1:109,668,057...109,683,997
Ensembl chr 1:109,668,022...109,709,551
|
|
G |
HEXB |
hexosaminidase subunit beta |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of HEXB protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:74,640,023...74,721,288
Ensembl chr 5:74,640,023...74,722,647
|
|
G |
HLA-DMB |
major histocompatibility complex, class II, DM beta |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RT1-DMB protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:32,934,636...32,941,028
Ensembl chr 6:32,934,629...32,941,028
|
|
G |
HLA-DQB1 |
major histocompatibility complex, class II, DQ beta 1 |
affects expression |
EXP |
Metronidazole affects the expression of HLA-DQB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:32,659,467...32,666,657
Ensembl chr 6:32,659,467...32,668,383
|
|
G |
HLA-DRB1 |
major histocompatibility complex, class II, DR beta 1 |
affects expression |
EXP |
Metronidazole affects the expression of HLA-DRB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:32,578,775...32,589,848
Ensembl chr 6:32,577,902...32,589,848
|
|
G |
HNRNPH2 |
heterogeneous nuclear ribonucleoprotein H2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HNRNPH2 protein |
CTD |
PMID:30545405 |
|
NCBI chr X:101,408,222...101,414,133
Ensembl chr X:101,408,222...101,414,133
|
|
G |
HP |
haptoglobin |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of HP protein |
CTD |
PMID:30545405 |
|
NCBI chr16:72,054,505...72,061,055
Ensembl chr16:72,054,505...72,061,055
|
|
G |
IL24 |
interleukin 24 |
increases expression |
EXP |
Metronidazole results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 1:206,897,443...206,904,139
Ensembl chr 1:206,897,443...206,904,139
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
ISO |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of IL6 protein] |
CTD |
PMID:31442584 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
KNG1 |
kininogen 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAP1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:186,717,359...186,744,410
Ensembl chr 3:186,717,348...186,744,410
|
|
G |
KRT16 |
keratin 16 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of KRT16 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:41,609,778...41,612,767
Ensembl chr17:41,609,778...41,615,899
|
|
G |
LEP |
leptin |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole co-treated with elemicin] results in increased expression of LEP mRNA |
CTD |
PMID:34979169 |
|
NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629
|
|
G |
LYZ |
lysozyme |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of LYZ2 protein |
CTD |
PMID:30545405 |
|
NCBI chr12:69,348,381...69,354,234
Ensembl chr12:69,348,381...69,354,234
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MAPK3 protein |
CTD |
PMID:30545405 |
|
NCBI chr16:30,114,105...30,123,220
Ensembl chr16:30,114,105...30,123,506
|
|
G |
MLXIP |
MLX interacting protein |
multiple interactions |
ISO |
[Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [elemicin results in increased expression of MLXIP mRNA] |
CTD |
PMID:34979169 |
|
NCBI chr12:122,078,756...122,147,344
Ensembl chr12:122,078,756...122,147,344
|
|
G |
MYH14 |
myosin heavy chain 14 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of MYH14 protein |
CTD |
PMID:30545405 |
|
NCBI chr19:50,203,622...50,310,540
Ensembl chr19:50,188,186...50,310,542
|
|
G |
NDUFA13 |
NADH:ubiquinone oxidoreductase subunit A13 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFA13 protein |
CTD |
PMID:30545405 |
|
NCBI chr19:19,516,225...19,528,198
Ensembl chr19:19,515,736...19,529,054
|
|
G |
NDUFAB1 |
NADH:ubiquinone oxidoreductase subunit AB1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of NDUFAB1 protein |
CTD |
PMID:30545405 |
|
NCBI chr16:23,581,014...23,596,316
Ensembl chr16:23,581,014...23,596,316
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Metronidazole inhibits the reaction [Indomethacin results in increased activity of NOS2 protein] |
CTD |
PMID:12568917 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NPC2 |
NPC intracellular cholesterol transporter 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of NPC2 protein |
CTD |
PMID:30545405 |
|
NCBI chr14:74,479,935...74,493,512
Ensembl chr14:74,476,192...74,494,177
|
|
G |
PFN1 |
profilin 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PFN1 protein |
CTD |
PMID:30545405 |
|
NCBI chr17:4,945,652...4,948,530
Ensembl chr17:4,945,652...4,949,061
|
|
G |
PGAM1 |
phosphoglycerate mutase 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PGAM1 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:97,426,191...97,433,444
Ensembl chr10:97,426,191...97,433,444
|
|
G |
PMM2 |
phosphomannomutase 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PMM2 protein |
CTD |
PMID:30545405 |
|
NCBI chr16:8,797,839...8,849,325
Ensembl chr16:8,788,823...8,862,534
|
|
G |
PPP1CA |
protein phosphatase 1 catalytic subunit alpha |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CA protein |
CTD |
PMID:30545405 |
|
NCBI chr11:67,398,183...67,401,858
Ensembl chr11:67,398,181...67,421,183
|
|
G |
PPP1CB |
protein phosphatase 1 catalytic subunit beta |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CB protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:28,751,604...28,802,940
Ensembl chr 2:28,751,640...28,802,940
|
|
G |
PPP1CC |
protein phosphatase 1 catalytic subunit gamma |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of PPP1CC protein |
CTD |
PMID:30545405 |
|
NCBI chr12:110,708,376...110,742,891
Ensembl chr12:110,719,680...110,742,939
|
|
G |
PSMA3 |
proteasome 20S subunit alpha 3 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of PSMA3 protein |
CTD |
PMID:30545405 |
|
NCBI chr14:58,244,843...58,272,004
Ensembl chr14:58,244,843...58,272,012
|
|
G |
RALB |
RAS like proto-oncogene B |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RALB protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:120,240,070...120,294,710
Ensembl chr 2:120,240,064...120,294,710
|
|
G |
RAN |
RAN, member RAS oncogene family |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RAN protein |
CTD |
PMID:30545405 |
|
NCBI chr12:130,872,066...130,877,678
Ensembl chr12:130,872,037...130,877,678
|
|
G |
RIDA |
reactive intermediate imine deaminase A homolog |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of RIDA protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:98,102,344...98,117,171
Ensembl chr 8:98,102,344...98,117,171
|
|
G |
RPL30 |
ribosomal protein L30 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPL30 protein |
CTD |
PMID:30545405 |
|
NCBI chr 8:98,041,721...98,045,545
Ensembl chr 8:98,024,851...98,046,469
|
|
G |
RPN2 |
ribophorin II |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPN2 protein |
CTD |
PMID:30545405 |
|
NCBI chr20:37,179,330...37,241,619
Ensembl chr20:37,178,410...37,241,619
|
|
G |
RPS23 |
ribosomal protein S23 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS23 protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:82,273,320...82,278,354
Ensembl chr 5:82,273,320...82,278,396
|
|
G |
RPS27L |
ribosomal protein S27 like |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of RPS27L protein |
CTD |
PMID:30545405 |
|
NCBI chr15:63,148,249...63,157,477
Ensembl chr15:63,125,872...63,158,021
|
|
G |
S100A10 |
S100 calcium binding protein A10 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A10 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:151,982,915...151,993,859
Ensembl chr 1:151,982,915...151,993,859
|
|
G |
S100A11 |
S100 calcium binding protein A11 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of S100A11 protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:152,032,506...152,037,004
Ensembl chr 1:152,032,506...152,047,907
|
|
G |
SCARB2 |
scavenger receptor class B member 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in decreased expression of SCARB2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 4:76,158,737...76,234,532
Ensembl chr 4:76,158,737...76,234,536
|
|
G |
SERPINB6 |
serpin family B member 6 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SERPINB6 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:2,948,159...2,971,793
Ensembl chr 6:2,948,159...2,972,165
|
|
G |
SHMT2 |
serine hydroxymethyltransferase 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SHMT2 protein |
CTD |
PMID:30545405 |
|
NCBI chr12:57,229,711...57,234,935
Ensembl chr12:57,229,573...57,234,935
|
|
G |
SLC3A1 |
solute carrier family 3 member 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SLC3A1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 2:44,275,480...44,322,437
Ensembl chr 2:44,275,458...44,321,494
|
|
G |
SLC51B |
solute carrier family 51 subunit beta |
decreases expression |
ISO |
Metronidazole results in decreased expression of SLC51B mRNA |
CTD |
PMID:24657338 |
|
NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
|
|
G |
SLCO2B1 |
solute carrier organic anion transporter family member 2B1 |
increases expression |
ISO |
Metronidazole results in increased expression of SLCO2B1 mRNA |
CTD |
PMID:24657338 |
|
NCBI chr11:75,151,107...75,206,549
Ensembl chr11:75,100,563...75,206,549
|
|
G |
SMPD2 |
sphingomyelin phosphodiesterase 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of SMPD2 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:109,440,724...109,443,919
Ensembl chr 6:109,440,724...109,443,919
|
|
G |
TARS1 |
threonyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TARS protein |
CTD |
PMID:30545405 |
|
NCBI chr 5:33,440,696...33,468,091
Ensembl chr 5:33,440,696...33,468,091
|
|
G |
TM9SF2 |
transmembrane 9 superfamily member 2 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TM9SF2 protein |
CTD |
PMID:30545405 |
|
NCBI chr13:99,501,472...99,564,048
Ensembl chr13:99,446,311...99,564,048
|
|
G |
TMED10 |
transmembrane p24 trafficking protein 10 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TMED10 protein |
CTD |
PMID:30545405 |
|
NCBI chr14:75,131,469...75,176,612
Ensembl chr14:75,131,469...75,176,612
|
|
G |
TNF |
tumor necrosis factor |
multiple interactions |
ISO |
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein; Dextran Sulfate inhibits the reaction [[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] results in decreased expression of TNF protein] |
CTD |
PMID:31442584 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TUBAL3 |
tubulin alpha like 3 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TUBAL3 protein |
CTD |
PMID:30545405 |
|
NCBI chr10:5,393,101...5,404,828
Ensembl chr10:5,393,101...5,404,828
|
|
G |
TWF1 |
twinfilin actin binding protein 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TWF1 protein |
CTD |
PMID:30545405 |
|
NCBI chr12:43,793,723...43,806,317
Ensembl chr12:43,793,723...43,806,328
|
|
G |
TXNDC5 |
thioredoxin domain containing 5 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of TXNDC5 protein |
CTD |
PMID:30545405 |
|
NCBI chr 6:7,881,517...7,910,788
Ensembl chr 6:7,881,517...7,910,788
|
|
G |
UQCRC1 |
ubiquinol-cytochrome c reductase core protein 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRC1 protein |
CTD |
PMID:30545405 |
|
NCBI chr 3:48,599,002...48,609,646
Ensembl chr 3:48,599,002...48,610,976
|
|
G |
UQCRFS1 |
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRFS1 protein |
CTD |
PMID:30545405 |
|
NCBI chr19:29,205,320...29,213,151
Ensembl chr19:29,205,320...29,213,151
|
|
G |
UQCRH |
ubiquinol-cytochrome c reductase hinge protein |
multiple interactions |
ISO |
[Ampicillin co-treated with Neomycin co-treated with Gentamicins co-treated with Metronidazole co-treated with Vancomycin] results in increased expression of UQCRH protein |
CTD |
PMID:30545405 |
|
NCBI chr 1:46,303,698...46,316,776
Ensembl chr 1:46,303,698...46,316,776
|
|
|
G |
PLAU |
plasminogen activator, urokinase |
decreases expression |
ISO |
Ornidazole results in decreased expression of PLAU mRNA; Ornidazole results in decreased expression of PLAU protein |
CTD |
PMID:18998460 |
|
NCBI chr10:73,909,164...73,917,494
Ensembl chr10:73,909,177...73,917,496
|
|
|
G |
AADAC |
arylacetamide deacetylase |
multiple interactions increases hydrolysis decreases acetylation |
EXP |
AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin] AADAC protein results in increased hydrolysis of Rifampin |
CTD |
PMID:21856291 PMID:22207054 |
|
NCBI chr 3:151,814,116...151,828,488
Ensembl chr 3:151,814,073...151,828,488
|
|
G |
ABCA1 |
ATP binding cassette subfamily A member 1 |
decreases expression increases expression |
EXP |
Rifampin results in decreased expression of ABCA1 mRNA; Rifampin results in decreased expression of ABCA1 protein Rifampin results in increased expression of ABCA1 mRNA; Rifampin results in increased expression of ABCA1 protein |
CTD |
PMID:15883047 PMID:17088262 |
|
NCBI chr 9:104,781,006...104,928,155
Ensembl chr 9:104,781,006...104,928,155
|
|
G |
ABCA2 |
ATP binding cassette subfamily A member 2 |
increases expression |
EXP |
Rifampin results in increased expression of ABCA2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:137,007,234...137,028,922
Ensembl chr 9:137,007,234...137,028,915
|
|
G |
ABCA8 |
ATP binding cassette subfamily A member 8 |
decreases expression |
EXP |
Rifampin results in decreased expression of ABCA8 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr17:68,867,289...68,955,392
Ensembl chr17:68,867,289...68,955,392
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects activity increases expression multiple interactions decreases activity |
EXP ISO |
Rifampin affects the activity of ABCB1 protein Rifampin results in increased expression of ABCB1 mRNA; Rifampin results in increased expression of ABCB1 protein [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter] |
CTD |
PMID:8632764 PMID:11744607 PMID:14722322 PMID:15276086 PMID:15290871 PMID:15710169 PMID:15964336 PMID:16819505 PMID:16837569 PMID:16842400 PMID:17003290 PMID:17191263 PMID:17365992 PMID:18094037 PMID:19148864 PMID:19647009 PMID:20018165 PMID:20041327 PMID:20624464 PMID:22258563 PMID:22914566 PMID:23685082 PMID:23707768 PMID:24259679 PMID:24552687 PMID:25313206 PMID:25542144 PMID:26301745 PMID:26394120 PMID:27199754 PMID:27871908 PMID:27918128 PMID:29356861 PMID:30071242 PMID:31233785 PMID:32092453 PMID:33002526 PMID:34689256 More...
|
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
decreases expression decreases activity multiple interactions |
EXP ISO |
Rifampin results in decreased expression of ABCB11 mRNA Rifampin results in decreased activity of ABCB11 protein Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:12135489 PMID:16837569 PMID:20829430 PMID:24014644 PMID:28437613 |
|
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
increases expression |
EXP |
Rifampin results in increased expression of ABCB4 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
|
|
G |
ABCB6 |
ATP binding cassette subfamily B member 6 (Langereis blood group) |
increases expression |
EXP |
Rifampin results in increased expression of ABCB6 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 2:219,209,772...219,218,958
Ensembl chr 2:219,209,772...219,218,994
|
|
G |
ABCC1 |
ATP binding cassette subfamily C member 1 |
increases expression |
EXP |
Rifampin results in increased expression of ABCC1 mRNA |
CTD |
PMID:17191263 |
|
NCBI chr16:15,949,143...16,143,053
Ensembl chr16:15,949,138...16,143,257
|
|
G |
ABCC10 |
ATP binding cassette subfamily C member 10 |
increases expression |
EXP |
Rifampin results in increased expression of ABCC10 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 6:43,427,541...43,451,994
Ensembl chr 6:43,427,366...43,450,427
|
|
G |
ABCC11 |
ATP binding cassette subfamily C member 11 |
increases expression |
EXP |
Rifampin results in increased expression of ABCC11 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr16:48,164,819...48,247,539
Ensembl chr16:48,165,773...48,247,568
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
affects export increases expression multiple interactions |
EXP |
ABCC2 protein affects the export of Rifampin Rifampin results in increased expression of ABCC2; Rifampin results in increased expression of ABCC2 mRNA; Rifampin results in increased expression of ABCC2 protein [Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein |
CTD |
PMID:11836020 PMID:12206135 PMID:15652233 PMID:16837569 PMID:16952291 PMID:20832446 PMID:25313206 PMID:27199754 More...
|
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases expression increases activity |
EXP |
[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; Rifampin inhibits the reaction [decitabine results in increased expression of ABCC3 mRNA] Rifampin results in increased expression of ABCC3 mRNA Rifampin results in increased activity of ABCC3 protein |
CTD |
PMID:14570758 PMID:16837569 PMID:16952291 PMID:19041851 PMID:20832446 PMID:23137910 PMID:27199754 More...
|
|
NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
|
|
G |
ABCC5 |
ATP binding cassette subfamily C member 5 |
increases expression |
EXP |
Rifampin results in increased expression of ABCC5 mRNA |
CTD |
PMID:19041851 |
|
NCBI chr 3:183,919,934...184,017,884
Ensembl chr 3:183,919,934...184,017,939
|
|
G |
ABCC6 |
ATP binding cassette subfamily C member 6 |
increases expression |
EXP |
Rifampin results in increased expression of ABCC6 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr16:16,149,565...16,223,494
Ensembl chr16:16,149,565...16,223,522
|
|
G |
ABCF1 |
ATP binding cassette subfamily F member 1 |
increases expression |
EXP |
Rifampin results in increased expression of ABCF1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 6:30,571,442...30,591,522
Ensembl chr 6:30,571,393...30,597,179
|
|
G |
ABCG1 |
ATP binding cassette subfamily G member 1 |
increases expression |
EXP |
Rifampin results in increased expression of ABCG1 mRNA; Rifampin results in increased expression of ABCG1 protein |
CTD |
PMID:12040753 PMID:17088262 |
|
NCBI chr21:42,199,689...42,297,244
Ensembl chr21:42,199,689...42,297,244
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (Junior blood group) |
increases expression |
EXP |
Rifampin results in increased expression of ABCG2 mRNA |
CTD |
PMID:16837569 PMID:27199754 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
G |
ABCG8 |
ATP binding cassette subfamily G member 8 |
increases expression |
EXP |
Rifampin results in increased expression of ABCG8 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988
|
|
G |
ABI3 |
ABI family member 3 |
decreases expression |
EXP |
Rifampin results in decreased expression of ABI3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:49,210,707...49,223,225
Ensembl chr17:49,210,411...49,223,225
|
|
G |
ACACA |
acetyl-CoA carboxylase alpha |
increases expression |
ISO |
Rifampin results in increased expression of ACACA mRNA |
CTD |
PMID:27806127 |
|
NCBI chr17:37,084,992...37,406,836
Ensembl chr17:37,084,992...37,406,836
|
|
G |
ACE2 |
angiotensin converting enzyme 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:15,518,197...15,607,211
Ensembl chr X:15,494,566...15,607,236
|
|
G |
ACTR10 |
actin related protein 10 |
increases expression |
EXP |
Rifampin results in increased expression of ACTR10 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr14:58,200,149...58,235,636
Ensembl chr14:58,200,080...58,235,636
|
|
G |
ADH1C |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
increases expression |
EXP |
Rifampin results in increased expression of ADH1C mRNA |
CTD |
PMID:12040753 |
|
NCBI chr 4:99,336,497...99,352,746
Ensembl chr 4:99,336,497...99,352,746
|
|
G |
ADIPOQ |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:33412187 |
|
NCBI chr 3:186,842,710...186,858,463
Ensembl chr 3:186,842,704...186,858,463
|
|
G |
ADORA2A |
adenosine A2a receptor |
decreases expression |
EXP |
Rifampin results in decreased expression of ADORA2A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr22:24,423,597...24,442,357
Ensembl chr22:24,417,879...24,442,357
|
|
G |
AGAP2 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of AGAP2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:57,723,761...57,742,161
Ensembl chr12:57,723,761...57,742,157
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions increases expression |
EXP |
[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in decreased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of AHR protein; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA] Rifampin results in increased expression of AHR mRNA; Rifampin results in increased expression of AHR protein |
CTD |
PMID:22733800 PMID:28428138 |
|
NCBI chr 7:17,298,652...17,346,147
Ensembl chr 7:16,916,359...17,346,152
|
|
G |
AKR1B10 |
aldo-keto reductase family 1 member B10 |
increases expression multiple interactions |
EXP |
Rifampin results in increased expression of AKR1B10 mRNA pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA] |
CTD |
PMID:29356861 |
|
NCBI chr 7:134,527,567...134,541,412
Ensembl chr 7:134,527,567...134,541,412
|
|
G |
ALAS1 |
5'-aminolevulinate synthase 1 |
increases expression |
EXP |
Rifampin results in increased expression of ALAS1 mRNA |
CTD |
PMID:24259679 PMID:24552687 |
|
NCBI chr 3:52,198,083...52,214,327
Ensembl chr 3:52,198,086...52,214,327
|
|
G |
ANGPTL3 |
angiopoietin like 3 |
decreases expression |
EXP |
Rifampin results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr 1:62,597,520...62,606,313
Ensembl chr 1:62,597,520...62,606,313
|
|
G |
ANGPTL4 |
angiopoietin like 4 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr19:8,364,155...8,374,370
Ensembl chr19:8,363,289...8,374,370
|
|
G |
ANKRD65 |
ankyrin repeat domain 65 |
decreases expression |
EXP |
Rifampin results in decreased expression of ANKRD65 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:1,418,420...1,421,276
Ensembl chr 1:1,418,420...1,421,769
|
|
G |
ANKS1B |
ankyrin repeat and sterile alpha motif domain containing 1B |
decreases expression |
EXP |
Rifampin results in decreased expression of ANKS1B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:98,734,786...99,984,936
Ensembl chr12:98,726,457...99,984,936
|
|
G |
ANXA5 |
annexin A5 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 4:121,667,946...121,696,980
Ensembl chr 4:121,667,946...121,696,995
|
|
G |
APOB |
apolipoprotein B |
affects secretion multiple interactions decreases expression |
EXP |
Rifampin affects the secretion of APOB protein ursodoxicoltaurine inhibits the reaction [Rifampin results in decreased expression of APOB mRNA] |
CTD |
PMID:32535746 |
|
NCBI chr 2:21,001,429...21,044,073
Ensembl chr 2:21,001,429...21,044,073
|
|
G |
APOC3 |
apolipoprotein C3 |
decreases secretion decreases expression |
EXP |
Rifampin results in decreased secretion of APOC3 protein Rifampin results in decreased expression of APOC3 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr11:116,829,907...116,833,072
Ensembl chr11:116,829,706...116,833,072
|
|
G |
AQP3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 9:33,441,160...33,447,593
Ensembl chr 9:33,441,156...33,447,596
|
|
G |
AQP4 |
aquaporin 4 |
decreases expression |
EXP |
Rifampin results in decreased expression of AQP4 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr18:26,852,038...26,865,803
Ensembl chr18:26,852,043...26,865,771
|
|
G |
ARSJ |
arylsulfatase family member J |
decreases expression |
EXP |
Rifampin results in decreased expression of ARSJ mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:113,900,284...113,979,647
Ensembl chr 4:113,900,284...113,979,727
|
|
G |
ATF3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of ATF3 mRNA |
CTD |
PMID:33629115 |
|
NCBI chr 1:212,565,407...212,620,777
Ensembl chr 1:212,565,334...212,620,777
|
|
G |
ATF4 |
activating transcription factor 4 |
multiple interactions increases expression |
ISO EXP |
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] Rifampin results in increased expression of ATF4 mRNA; Rifampin results in increased expression of ATF4 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 protein] |
CTD |
PMID:24638036 PMID:27470132 |
|
NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,683
|
|
G |
ATF6 |
activating transcription factor 6 |
increases expression |
EXP |
Rifampin results in increased expression of ATF6 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,298...161,977,574
|
|
G |
ATM |
ATM serine/threonine kinase |
multiple interactions decreases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein Rifampin results in decreased expression of ATM mRNA |
CTD |
PMID:21224054 PMID:24552687 |
|
NCBI chr11:108,223,067...108,369,102
Ensembl chr11:108,223,044...108,369,102
|
|
G |
ATP6V0A1 |
ATPase H+ transporting V0 subunit a1 |
multiple interactions increases expression |
EXP |
[Rotenone co-treated with Rifampin] results in increased expression of ATP6V0A1 protein; Rifampin inhibits the reaction [Rotenone results in decreased expression of ATP6V0A1 mRNA]; Rotenone inhibits the reaction [Rifampin results in increased expression of ATP6V0A1 protein] |
CTD |
PMID:31648047 |
|
NCBI chr17:42,458,878...42,522,579
Ensembl chr17:42,458,844...42,522,582
|
|
G |
ATP6V0D1 |
ATPase H+ transporting V0 subunit d1 |
multiple interactions |
EXP |
ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]] |
CTD |
PMID:31648047 |
|
NCBI chr16:67,438,019...67,481,157
Ensembl chr16:67,438,014...67,481,181
|
|
G |
ATRX |
ATRX chromatin remodeler |
increases expression |
EXP |
Rifampin results in increased expression of ATRX mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:77,504,880...77,786,216
Ensembl chr X:77,504,880...77,786,233
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression |
ISO EXP |
[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of BAX mRNA; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein] [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein Rifampin results in decreased expression of BAX protein |
CTD |
PMID:11958592 PMID:12645856 PMID:21224054 PMID:21419764 PMID:31629065 PMID:33629115 More...
|
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
increases expression multiple interactions |
EXP ISO |
Rifampin results in increased expression of BCL2 protein [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein [Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein] |
CTD |
PMID:11958592 PMID:21419764 PMID:31629065 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BCL2L1 |
BCL2 like 1 |
increases expression multiple interactions |
EXP ISO |
Rifampin results in increased expression of BCL2L1 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:11958592 PMID:12645856 PMID:21224054 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
BHLHE40 |
basic helix-loop-helix family member e40 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 3:4,979,437...4,985,323
Ensembl chr 3:4,979,437...4,985,323
|
|
G |
BMP4 |
bone morphogenetic protein 4 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr14:53,949,736...53,956,891
Ensembl chr14:53,949,736...53,958,761
|
|
G |
BRDTP1 |
bromodomain testis associated pseudogene 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of BRDTP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:96,337,086...96,337,902
Ensembl chr X:96,337,236...96,337,912
|
|
G |
C4orf51 |
chromosome 4 open reading frame 51 |
decreases expression |
EXP |
Rifampin results in decreased expression of C4ORF51 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:145,680,146...145,792,443
Ensembl chr 4:145,680,146...145,771,032
|
|
G |
C9orf153 |
chromosome 9 open reading frame 153 |
decreases expression |
EXP |
Rifampin results in decreased expression of C9ORF153 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:86,220,265...86,259,657
Ensembl chr 9:86,220,265...86,259,657
|
|
G |
CA1 |
carbonic anhydrase 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of CA1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:85,327,608...85,378,113
Ensembl chr 8:85,327,608...85,379,014
|
|
G |
CASP1 |
caspase 1 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [Rotenone results in increased cleavage of CASP1 protein] |
CTD |
PMID:26086368 |
|
NCBI chr11:105,025,443...105,036,686
Ensembl chr11:105,025,397...105,035,250
|
|
G |
CASP3 |
caspase 3 |
multiple interactions |
EXP ISO |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein] [Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein] |
CTD |
PMID:11958592 PMID:12645856 PMID:17936189 PMID:21419764 PMID:23764483 PMID:26775663 PMID:31678598 More...
|
|
NCBI chr 4:184,627,696...184,649,447
Ensembl chr 4:184,627,696...184,649,509
|
|
G |
CASP8 |
caspase 8 |
multiple interactions |
EXP |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein] |
CTD |
PMID:11958592 PMID:12645856 |
|
NCBI chr 2:201,233,443...201,287,711
Ensembl chr 2:201,233,443...201,361,836
|
|
G |
CBR3 |
carbonyl reductase 3 |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of CBR3 mRNA |
CTD |
PMID:33629115 |
|
NCBI chr21:36,135,079...36,146,562
Ensembl chr21:36,135,079...36,146,562
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of CCL2 mRNA |
CTD |
PMID:25051504 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCL5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Rifampin results in decreased expression of CCL5 protein |
CTD |
PMID:25051504 |
|
NCBI chr17:35,871,491...35,880,360
Ensembl chr17:35,871,491...35,880,793
|
|
G |
CCN1 |
cellular communication network factor 1 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:85,580,761...85,583,950
Ensembl chr 1:85,580,761...85,584,589
|
|
G |
CCND1 |
cyclin D1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CCNG1 |
cyclin G1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 5:163,437,571...163,457,640
Ensembl chr 5:163,437,569...163,446,151
|
|
G |
CCR6 |
C-C motif chemokine receptor 6 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 6:167,111,795...167,139,141
Ensembl chr 6:167,111,807...167,139,141
|
|
G |
CCR7 |
C-C motif chemokine receptor 7 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:40,553,769...40,565,472
Ensembl chr17:40,553,769...40,565,472
|
|
G |
CD36 |
CD36 molecule |
increases expression |
ISO |
Rifampin results in increased expression of CD36 mRNA |
CTD |
PMID:27806127 |
|
NCBI chr 7:80,602,207...80,679,274
Ensembl chr 7:80,369,575...80,679,277
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein |
CTD |
PMID:21224054 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,337
|
|
G |
CDKN2B |
cyclin dependent kinase inhibitor 2B |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 9:22,002,903...22,009,313
Ensembl chr 9:22,002,903...22,009,305
|
|
G |
CEBPA |
CCAAT enhancer binding protein alpha |
multiple interactions |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPA mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein] |
CTD |
PMID:33412187 |
|
NCBI chr19:33,299,934...33,302,534
Ensembl chr19:33,299,934...33,302,534
|
|
G |
CEBPB |
CCAAT enhancer binding protein beta |
multiple interactions |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPB mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein] |
CTD |
PMID:33412187 |
|
NCBI chr20:50,190,583...50,192,690
Ensembl chr20:50,190,830...50,192,668
|
|
G |
CEBPD |
CCAAT enhancer binding protein delta |
multiple interactions |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPD mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA] |
CTD |
PMID:33412187 |
|
NCBI chr 8:47,736,913...47,738,164
Ensembl chr 8:47,736,913...47,738,164
|
|
G |
CES1 |
carboxylesterase 1 |
increases expression |
EXP |
Rifampin results in increased expression of CES1 protein |
CTD |
PMID:10640517 |
|
NCBI chr16:55,802,851...55,833,096
Ensembl chr16:55,802,851...55,833,337
|
|
G |
CES2 |
carboxylesterase 2 |
increases expression multiple interactions |
EXP |
Rifampin results in increased expression of CES2 mRNA; Rifampin results in increased expression of CES2 protein Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA] |
CTD |
PMID:10640517 PMID:17003103 |
|
NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096
|
|
G |
CFLAR |
CASP8 and FADD like apoptosis regulator |
multiple interactions increases expression |
EXP |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form] Rifampin results in increased expression of CFLAR protein |
CTD |
PMID:11958592 PMID:12645856 |
|
NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687
|
|
G |
CHEK2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr22:28,687,743...28,741,834
Ensembl chr22:28,687,743...28,742,422
|
|
G |
CIZ1 |
CDKN1A interacting zinc finger protein 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of CIZ1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:128,166,065...128,204,222
Ensembl chr 9:128,161,251...128,204,383
|
|
G |
CLK2 |
CDC like kinase 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of CLK2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:155,262,868...155,273,504
Ensembl chr 1:155,262,868...155,278,491
|
|
G |
CNTLN |
centlein |
increases expression |
EXP |
Rifampin results in increased expression of CNTLN mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:17,135,040...17,528,634
Ensembl chr 9:17,134,982...17,503,923
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
Rifampin results in increased expression of CPT1A mRNA |
CTD |
PMID:27806127 |
|
NCBI chr11:68,754,620...68,844,277
Ensembl chr11:68,754,620...68,844,410
|
|
G |
CRHR1 |
corticotropin releasing hormone receptor 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of CRHR1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:45,784,320...45,835,828
Ensembl chr17:45,784,280...45,835,828
|
|
G |
CRP |
C-reactive protein |
multiple interactions |
EXP |
[Floxacillin co-treated with Gentamicins co-treated with Rifampin] results in increased expression of CRP protein |
CTD |
PMID:16943303 |
|
NCBI chr 1:159,712,289...159,714,589
Ensembl chr 1:159,712,289...159,714,589
|
|
G |
CSNK1G1 |
casein kinase 1 gamma 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of CSNK1G1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:64,165,525...64,356,173
Ensembl chr15:64,165,525...64,356,173
|
|
G |
CXCL1 |
C-X-C motif chemokine ligand 1 |
increases expression |
ISO |
Rifampin results in increased expression of CXCL1 protein |
CTD |
PMID:25051504 |
|
NCBI chr 4:73,869,393...73,871,308
Ensembl chr 4:73,869,393...73,871,308
|
|
G |
CXCL10 |
C-X-C motif chemokine ligand 10 |
multiple interactions affects expression |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA Rifampin affects the expression of CXCL10 protein |
CTD |
PMID:21224054 PMID:25051504 |
|
NCBI chr 4:76,021,118...76,023,497
Ensembl chr 4:76,021,118...76,023,497
|
|
G |
CYB5RL |
cytochrome b5 reductase like |
increases expression |
EXP |
Rifampin results in increased expression of CYB5RL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:54,169,651...54,200,030
Ensembl chr 1:54,169,651...54,200,036
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions increases activity increases expression |
ISO EXP |
Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Rifampin results in increased activity of CYP1A1 protein Rifampin results in increased expression of CYP1A1 mRNA; Rifampin results in increased expression of CYP1A1 protein [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP1A1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 protein; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A1 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:12040753 PMID:18493746 PMID:19118567 PMID:19409404 PMID:22733800 PMID:24999631 PMID:29162470 More...
|
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
multiple interactions increases expression |
EXP ISO |
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A2 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] Rifampin results in increased expression of CYP1A2 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein Rifampin results in increased expression of CYP1A2 mRNA; Rifampin results in increased expression of CYP1A2 protein |
CTD |
PMID:15977188 PMID:17590308 PMID:18493746 PMID:25835148 PMID:29162470 PMID:30503582 More...
|
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP1B1 |
cytochrome P450 family 1 subfamily B member 1 |
multiple interactions |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1B1 mRNA |
CTD |
PMID:21224054 PMID:29162470 |
|
NCBI chr 2:38,067,509...38,076,151
Ensembl chr 2:38,066,973...38,109,902
|
|
G |
CYP24A1 |
cytochrome P450 family 24 subfamily A member 1 |
multiple interactions increases expression increases activity |
EXP |
NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter] Rifampin results in increased activity of CYP24A1 protein |
CTD |
PMID:15630458 PMID:21127053 |
|
NCBI chr20:54,143,538...54,173,986
Ensembl chr20:54,153,446...54,173,986
|
|
G |
CYP26A1 |
cytochrome P450 family 26 subfamily A member 1 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:93,073,475...93,077,885
Ensembl chr10:93,073,475...93,077,885
|
|
G |
CYP27A1 |
cytochrome P450 family 27 subfamily A member 1 |
multiple interactions increases expression |
EXP |
Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene] Rifampin results in increased expression of CYP27A1 mRNA |
CTD |
PMID:17088262 |
|
NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293
|
|
G |
CYP2A13 |
cytochrome P450 family 2 subfamily A member 13 |
decreases expression increases expression |
EXP ISO |
Rifampin results in decreased expression of CYP2A13 mRNA Rifampin results in increased expression of CYP2A1 mRNA Rifampin results in increased expression of CYP2A13 mRNA |
CTD |
PMID:19118567 PMID:22258563 |
|
NCBI chr19:41,088,451...41,096,195
Ensembl chr19:41,088,451...41,096,195
|
|
G |
CYP2A6 |
cytochrome P450 family 2 subfamily A member 6 |
multiple interactions increases activity increases expression |
EXP ISO |
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP2A6 mRNA; Rifampin promotes the reaction [NR1I2 protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [PPARGC1A protein binds to CYP2A6 promoter] Rifampin results in increased activity of CYP2A5 protein Rifampin results in increased expression of CYP2A5 mRNA [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA Rifampin results in increased expression of CYP2A6 mRNA; Rifampin results in increased expression of CYP2A6 protein |
CTD |
PMID:11038160 PMID:14709624 PMID:15629111 PMID:16857725 PMID:19118567 PMID:21224054 PMID:24038852 PMID:24830941 PMID:25929522 PMID:26196221 PMID:29162470 PMID:30503582 More...
|
|
NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447
|
|
G |
CYP2A7 |
cytochrome P450 family 2 subfamily A member 7 |
increases expression |
ISO |
Rifampin results in increased expression of CYP2A4 mRNA |
CTD |
PMID:30503582 |
|
NCBI chr19:40,875,439...40,882,231
Ensembl chr19:40,875,439...40,882,752
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
multiple interactions increases expression increases activity |
ISO EXP |
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B6 mRNA; Rifampin results in increased expression of CYP2B6 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2B6 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP2B6 protein Rifampin results in increased activity of CYP2B6 protein |
CTD |
PMID:12040753 PMID:12571232 PMID:12695351 PMID:14709624 PMID:14977870 PMID:15548381 PMID:15629111 PMID:15802389 PMID:16608920 PMID:17041008 PMID:17438109 PMID:17954527 PMID:18094037 PMID:18332078 PMID:19118567 PMID:19202563 PMID:19497361 PMID:20035023 PMID:20361990 PMID:21224054 PMID:21315811 PMID:22126990 PMID:22258563 PMID:22524704 PMID:22733800 PMID:23732298 PMID:24038852 PMID:24259679 PMID:24552687 PMID:25313206 PMID:25835148 PMID:25929522 PMID:26196221 PMID:27871908 PMID:27917125 PMID:28289823 PMID:28887089 PMID:29356861 PMID:30071242 PMID:30503582 PMID:34689256 More...
|
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP2C18 |
cytochrome P450 family 2 subfamily C member 18 |
decreases expression |
EXP |
Rifampin results in decreased expression of CYP2C18 mRNA; Rifampin results in decreased expression of CYP2C18 protein |
CTD |
PMID:22258563 PMID:31629065 |
|
NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190
|
|
G |
CYP2C19 |
cytochrome P450 family 2 subfamily C member 19 |
multiple interactions increases activity increases expression |
EXP |
Rifampin results in increased expression of and results in increased activity of CYP2C19 protein Rifampin results in increased activity of CYP2C19 protein Rifampin results in increased expression of CYP2C19 mRNA; Rifampin results in increased expression of CYP2C19 protein |
CTD |
PMID:12584154 PMID:14709624 PMID:15629111 PMID:17954527 PMID:19118567 PMID:22126990 PMID:22310298 PMID:24552687 PMID:24830941 PMID:27917125 More...
|
|
NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
|
|
G |
CYP2C8 |
cytochrome P450 family 2 subfamily C member 8 |
affects binding increases expression multiple interactions increases activity |
EXP ISO |
[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter Rifampin results in increased expression of CYP2C29 mRNA [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine] [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein Rifampin results in increased expression of CYP2C8 mRNA; Rifampin results in increased expression of CYP2C8 protein Rifampin results in increased activity of CYP2C8 protein |
CTD |
PMID:12040753 PMID:15771232 PMID:15933212 PMID:17954527 PMID:19118567 PMID:22126990 PMID:25313206 PMID:25835148 PMID:29356861 PMID:30503582 PMID:31629065 More...
|
|
NCBI chr10:95,036,772...95,069,497
Ensembl chr10:95,036,772...95,069,497
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
multiple interactions increases activity increases expression |
EXP |
Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP2C9 mRNA]; Rifampin results in increased activity of and results in increased expression of CYP2C9 protein; Rifampin results in increased expression of and results in increased activity of CYP2C9 protein Rifampin results in increased activity of CYP2C9 protein Rifampin results in increased expression of CYP2C9 mRNA; Rifampin results in increased expression of CYP2C9 protein |
CTD |
PMID:14600250 PMID:14709624 PMID:14722322 PMID:15629111 PMID:15802389 PMID:15919766 PMID:16267138 PMID:16608920 PMID:17590308 PMID:17954527 PMID:19041297 PMID:19118567 PMID:19202563 PMID:19497360 PMID:19686824 PMID:21292004 PMID:22126990 PMID:22843569 PMID:24259679 PMID:24552687 PMID:24830941 PMID:25929522 PMID:26196221 PMID:27590069 PMID:27794450 PMID:27917125 PMID:28887089 PMID:34689256 More...
|
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP2D6 |
cytochrome P450 family 2 subfamily D member 6 |
increases expression decreases expression |
EXP ISO |
Rifampin results in increased expression of CYP2D6 mRNA Rifampin results in decreased expression of CYP2D22 mRNA |
CTD |
PMID:19041851 PMID:30503582 PMID:33844597 |
|
NCBI chr22:42,126,499...42,130,810
Ensembl chr22:42,126,499...42,130,865
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
increases activity decreases expression multiple interactions increases expression |
EXP ISO |
Rifampin results in increased activity of CYP2E1 protein Rifampin results in decreased expression of CYP2E1 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein Rifampin results in increased expression of CYP2E1 mRNA; Rifampin results in increased expression of CYP2E1 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2E1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 protein [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein] |
CTD |
PMID:15132840 PMID:18071298 PMID:22258563 PMID:22733800 PMID:25835148 PMID:27919644 PMID:30503582 More...
|
|
NCBI chr10:133,527,363...133,539,123
Ensembl chr10:133,520,406...133,561,220
|
|
G |
CYP2F1 |
cytochrome P450 family 2 subfamily F member 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of CYP2F1 mRNA |
CTD |
PMID:22258563 |
|
NCBI chr19:41,114,432...41,128,381
Ensembl chr19:41,114,432...41,128,381
|
|
G |
CYP2J2 |
cytochrome P450 family 2 subfamily J member 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of CYP2J2 mRNA |
CTD |
PMID:33263786 |
|
NCBI chr 1:59,893,308...59,969,212
Ensembl chr 1:59,893,308...59,926,773
|
|
G |
CYP2S1 |
cytochrome P450 family 2 subfamily S member 1 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr19:41,193,219...41,207,539
Ensembl chr19:41,193,210...41,207,539
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
affects activity increases expression multiple interactions decreases response to substance increases activity |
EXP ISO |
Rifampin affects the activity of CYP3A4 protein Rifampin results in increased expression of CYP3A2 mRNA; Rifampin results in increased expression of CYP3A4 mRNA [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A2 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A2 protein CYP3A4 protein results in decreased susceptibility to Rifampin [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA; [HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP3A4 mRNA; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP3A4 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Ethinyl Estradiol; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [Rifampin results in increased expression of CYP3A4 protein] which results in increased hydroxylation of Testosterone; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Arsenic Trioxide inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 4-hydroxymidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased hydroxylation of Midazolam]; Dexamethasone promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Econazole promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; lorlatinib inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin binds to and results in increased activity of CYP3A4 protein; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [Calcitriol results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased metabolism of Lidocaine]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A4 protein; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; sulforaphane inhibits the reaction [Rifampin results in increased expression of CYP3A4]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; trichostatin A affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; trichostatin A promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] [Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of CYP3A4 protein Rifampin results in increased expression of CYP3A4; Rifampin results in increased expression of CYP3A4 mRNA; Rifampin results in increased expression of CYP3A4 mRNA alternative form; Rifampin results in increased expression of CYP3A4 protein |
CTD |
PMID:8632764 PMID:9298257 PMID:9512926 PMID:10219967 PMID:10640517 PMID:10859152 PMID:11581012 PMID:12040753 PMID:12065438 PMID:12072427 PMID:12235278 PMID:12417264 PMID:12505310 PMID:12584154 PMID:12642470 PMID:12673034 PMID:12695340 PMID:12695342 PMID:12851153 PMID:14600250 PMID:14636322 PMID:14709624 PMID:14722322 PMID:14977870 PMID:15075359 PMID:15466163 PMID:15548381 PMID:15554232 PMID:15629111 PMID:15681896 PMID:15710169 PMID:15769886 PMID:15771232 PMID:15802389 PMID:15833926 PMID:15855724 PMID:15964336 PMID:15977188 PMID:16146350 PMID:16184197 PMID:16565514 PMID:16608920 PMID:16632523 PMID:16819505 PMID:16837568 PMID:17003103 PMID:17041008 PMID:17270371 PMID:17293382 PMID:17438109 PMID:17590308 PMID:17936189 PMID:17954527 PMID:17998298 PMID:18094037 PMID:18332045 PMID:18332078 PMID:18505790 PMID:18799805 PMID:18839173 PMID:19041297 PMID:19118567 PMID:19135037 PMID:19202563 PMID:19230594 PMID:19686824 PMID:19854261 PMID:20035023 PMID:20035846 PMID:20233841 PMID:20361990 PMID:20599501 PMID:21127053 PMID:21292004 PMID:21315811 PMID:21402137 PMID:21641981 PMID:21742782 PMID:21764778 PMID:21856291 PMID:21920351 PMID:21924250 PMID:21998292 PMID:22093699 PMID:22126990 PMID:22159698 PMID:22178124 PMID:22258563 PMID:22310298 PMID:22310326 PMID:22314385 PMID:22524704 PMID:22664347 PMID:22687401 PMID:22733800 PMID:22843569 PMID:22982774 PMID:23153560 PMID:23707768 PMID:23732298 PMID:23845848 PMID:23850985 PMID:23899473 PMID:24038852 PMID:24146111 PMID:24204015 PMID:24259679 PMID:24552687 PMID:24685772 PMID:24752503 PMID:24999631 PMID:25069801 PMID:25084468 PMID:25313206 PMID:25455453 PMID:25512232 PMID:25542144 PMID:25616597 PMID:25929522 PMID:26196221 PMID:26201057 PMID:26301745 PMID:26341324 PMID:26616219 PMID:27177772 PMID:27180241 PMID:27507784 PMID:27590069 PMID:27794450 PMID:27871908 PMID:27917125 PMID:27919644 PMID:28289823 PMID:28571685 PMID:28887089 PMID:28916285 PMID:29162470 PMID:29356861 PMID:29933105 PMID:30071242 PMID:30087611 PMID:31132328 PMID:31233785 PMID:31870919 PMID:31877331 PMID:32092453 PMID:32682830 PMID:33002526 PMID:33263786 PMID:33629115 PMID:33844597 PMID:34021354 PMID:34689256 More...
|
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
increases expression multiple interactions |
EXP ISO |
Rifampin results in increased expression of CYP3A5 mRNA Rifampin results in increased expression of CYP3A11 mRNA; Rifampin results in increased expression of CYP3A11 protein [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CYP3A11 mRNA; sulforaphane inhibits the reaction [Rifampin results in increased expression of CYP3A11 mRNA] |
CTD |
PMID:12040753 PMID:12673034 PMID:15629111 PMID:15681896 PMID:19118567 PMID:20832446 PMID:20869979 PMID:21224054 PMID:22467028 PMID:23153560 PMID:24146111 PMID:24259679 PMID:25835148 PMID:27806127 PMID:28496040 PMID:30503582 More...
|
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,998
|
|
G |
CYP3A7 |
cytochrome P450 family 3 subfamily A member 7 |
increases expression |
EXP |
Rifampin results in increased expression of CYP3A7 mRNA |
CTD |
PMID:12673034 PMID:19118567 PMID:22258563 PMID:24146111 PMID:24552687 PMID:32682830 More...
|
|
NCBI chr 7:99,705,036...99,735,196
Ensembl chr 7:99,705,036...99,735,196
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions decreases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA Rifampin results in decreased expression of CYP7A1 mRNA NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:15629111 PMID:21127053 PMID:21224054 PMID:22258563 PMID:24259679 PMID:34689256 More...
|
|
NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
|
|
G |
CYP8B1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898
|
|
G |
DCAF5 |
DDB1 and CUL4 associated factor 5 |
decreases expression |
EXP |
Rifampin results in decreased expression of DCAF5 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr14:69,050,881...69,153,197
Ensembl chr14:69,050,881...69,153,150
|
|
G |
DCLRE1B |
DNA cross-link repair 1B |
decreases expression |
EXP |
Rifampin results in decreased expression of DCLRE1B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:113,904,619...113,914,086
Ensembl chr 1:113,905,213...113,914,086
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions increases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of DDIT3 mRNA] Rifampin results in increased expression of DDIT3 mRNA; Rifampin results in increased expression of DDIT3 protein |
CTD |
PMID:21224054 PMID:27470132 PMID:32535746 PMID:33629115 |
|
NCBI chr12:57,516,588...57,521,698
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DHCR24 |
24-dehydrocholesterol reductase |
multiple interactions |
EXP |
[Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA |
CTD |
PMID:22101211 |
|
NCBI chr 1:54,849,627...54,887,195
Ensembl chr 1:54,849,627...54,887,195
|
|
G |
DIO1 |
iodothyronine deiodinase 1 |
increases expression |
EXP |
Rifampin results in increased expression of DIO1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:53,894,187...53,911,086
Ensembl chr 1:53,891,239...53,911,086
|
|
G |
DLX4 |
distal-less homeobox 4 |
decreases expression |
EXP |
Rifampin results in decreased expression of DLX4 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:49,968,572...49,974,959
Ensembl chr17:49,968,970...49,974,959
|
|
G |
DNAJA1 |
DnaJ heat shock protein family (Hsp40) member A1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 9:33,025,273...33,039,907
Ensembl chr 9:33,025,273...33,039,907
|
|
G |
E2F1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr20:33,675,477...33,686,385
Ensembl chr20:33,675,477...33,686,385
|
|
G |
EDN1 |
endothelin 1 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 6:12,256,484...12,297,194
Ensembl chr 6:12,290,361...12,297,194
|
|
G |
EGR1 |
early growth response 1 |
multiple interactions |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA |
CTD |
PMID:21127053 PMID:21224054 |
|
NCBI chr 5:138,465,479...138,469,303
Ensembl chr 5:138,465,479...138,469,303
|
|
G |
EGR2 |
early growth response 2 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:62,811,996...62,819,167
Ensembl chr10:62,811,996...62,819,167
|
|
G |
EGR4 |
early growth response 4 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 2:73,290,929...73,293,548
Ensembl chr 2:73,290,929...73,293,701
|
|
G |
EIF2AK3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation increases expression multiple interactions |
ISO EXP |
Rifampin results in increased phosphorylation of EIF2AK3 protein Rifampin results in increased expression of EIF2AK3 mRNA; Rifampin results in increased expression of EIF2AK3 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 protein] |
CTD |
PMID:24638036 PMID:27470132 |
|
NCBI chr 2:88,556,741...88,628,145
Ensembl chr 2:88,556,741...88,691,518
|
|
G |
EIF2S1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
ISO |
Rifampin results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:24638036 |
|
NCBI chr14:67,360,328...67,386,516
Ensembl chr14:67,360,328...67,386,516
|
|
G |
ELK1 |
ETS transcription factor ELK1 |
decreases expression |
EXP |
Rifampin results in decreased expression of ELK1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:47,635,520...47,650,604
Ensembl chr X:47,635,521...47,650,604
|
|
G |
EPAS1 |
endothelial PAS domain protein 1 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 2:46,297,407...46,386,697
Ensembl chr 2:46,293,667...46,386,697
|
|
G |
EPHA1-AS1 |
EPHA1 antisense RNA 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of EPHA1-AS1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:143,407,813...143,523,449
Ensembl chr 7:143,407,784...143,523,449
|
|
G |
EPHX1 |
epoxide hydrolase 1 |
increases expression multiple interactions |
EXP |
Rifampin results in increased expression of EPHX1 mRNA pimecrolimus inhibits the reaction [Rifampin results in increased expression of EPHX1 mRNA] |
CTD |
PMID:22258563 PMID:25313206 PMID:29356861 |
|
NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563
|
|
G |
ERN1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases expression |
EXP |
Rifampin results in increased expression of and results in increased phosphorylation of ERN1 protein Rifampin results in increased expression of ERN1 mRNA |
CTD |
PMID:32535746 |
|
NCBI chr17:64,039,142...64,130,144
Ensembl chr17:64,039,080...64,130,819
|
|
G |
ETNPPL |
ethanolamine-phosphate phospho-lyase |
increases expression |
EXP |
Rifampin results in increased expression of ETNPPL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:108,742,053...108,763,053
Ensembl chr 4:108,742,048...108,763,054
|
|
G |
F13B |
coagulation factor XIII B chain |
increases expression |
EXP |
Rifampin results in increased expression of F13B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:197,038,741...197,067,260
Ensembl chr 1:197,038,741...197,067,260
|
|
G |
FAM200A |
family with sequence similarity 200 member A |
increases expression |
EXP |
Rifampin results in increased expression of FAM200A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:99,546,300...99,558,543
Ensembl chr 7:99,546,300...99,558,536
|
|
G |
FAM230C |
family with sequence similarity 230 member C |
decreases expression |
EXP |
Rifampin results in decreased expression of FAM230C mRNA |
CTD |
PMID:24552687 |
|
NCBI chr13:18,195,297...18,232,016
Ensembl chr13:18,195,297...18,232,024
|
|
G |
FAM66D |
family with sequence similarity 66 member D |
decreases expression |
EXP |
Rifampin results in decreased expression of FAM66D mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:12,115,782...12,151,189
Ensembl chr 8:12,115,767...12,177,550
|
|
G |
FAS |
Fas cell surface death receptor |
multiple interactions |
EXP |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein] |
CTD |
PMID:11958592 PMID:12645856 |
|
NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
|
|
G |
FASLG |
Fas ligand |
multiple interactions decreases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA Rifampin results in decreased expression of FASLG mRNA; Rifampin results in decreased expression of FASLG protein Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein] |
CTD |
PMID:11958592 PMID:12645856 PMID:21224054 PMID:24552687 |
|
NCBI chr 1:172,659,103...172,666,876
Ensembl chr 1:172,659,103...172,666,876
|
|
G |
FASN |
fatty acid synthase |
increases expression affects expression multiple interactions |
ISO EXP |
Rifampin results in increased expression of FASN mRNA Rifampin affects the expression of FASN mRNA pimecrolimus inhibits the reaction [Rifampin results in increased expression of FASN mRNA] |
CTD |
PMID:27806127 PMID:29356861 PMID:34689256 |
|
NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
|
|
G |
FGF19 |
fibroblast growth factor 19 |
multiple interactions increases expression |
EXP |
[Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA Rifampin results in increased expression of FGF19 mRNA |
CTD |
PMID:17696253 |
|
NCBI chr11:69,698,238...69,704,022
Ensembl chr11:69,698,238...69,704,022
|
|
G |
FMO1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 1:171,248,494...171,285,978
Ensembl chr 1:171,248,471...171,285,978
|
|
G |
FMO4 |
flavin containing dimethylaniline monoxygenase 4 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 1:171,314,183...171,342,084
Ensembl chr 1:171,314,183...171,342,084
|
|
G |
FOXA1 |
forkhead box A1 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr14:37,589,552...37,595,249
Ensembl chr14:37,589,552...37,596,059
|
|
G |
FOXP1 |
forkhead box P1 |
increases expression |
EXP |
Rifampin results in increased expression of FOXP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:70,954,708...71,583,978
Ensembl chr 3:70,954,693...71,583,978
|
|
G |
FUT1 |
fucosyltransferase 1 (H blood group) |
decreases expression |
EXP |
Rifampin results in decreased expression of FUT1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr19:48,748,011...48,755,358
Ensembl chr19:48,748,011...48,755,390
|
|
G |
G6PC1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions decreases expression affects expression |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA] Rifampin results in decreased expression of G6PC mRNA |
CTD |
PMID:24204015 PMID:34689256 |
|
NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438
|
|
G |
GADD45A |
growth arrest and DNA damage inducible alpha |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334
|
|
G |
GADD45B |
growth arrest and DNA damage inducible beta |
multiple interactions |
EXP |
NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA] |
CTD |
PMID:21127053 |
|
NCBI chr19:2,476,127...2,478,257
Ensembl chr19:2,476,122...2,478,259
|
|
G |
GATA5 |
GATA binding protein 5 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr20:62,463,497...62,475,995
Ensembl chr20:62,463,497...62,475,995
|
|
G |
GCK |
glucokinase |
decreases expression multiple interactions |
EXP |
Rifampin results in decreased expression of GCK protein NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein] |
CTD |
PMID:26616219 |
|
NCBI chr 7:44,143,213...44,189,439
Ensembl chr 7:44,143,213...44,198,170
|
|
G |
GCOM1 |
GCOM1, MYZAP-POLR2M combined locus |
decreases expression |
EXP |
Rifampin results in decreased expression of GCOM1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:57,591,904...57,717,557
Ensembl chr15:57,591,908...57,714,745
|
|
G |
GLIS2 |
GLIS family zinc finger 2 |
increases expression |
EXP |
Rifampin results in increased expression of GLIS2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr16:4,314,761...4,339,595
Ensembl chr16:4,314,761...4,339,597
|
|
G |
GNAL |
G protein subunit alpha L |
decreases expression |
EXP |
Rifampin results in decreased expression of GNAL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr18:11,689,264...11,885,685
Ensembl chr18:11,689,264...11,885,685
|
|
G |
GPT |
glutamic--pyruvic transaminase |
multiple interactions increases expression |
EXP ISO |
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of GPT protein]; [Rifampin co-treated with Acetaminophen] results in decreased activity of GPT protein Rifampin inhibits the reaction [Acetaminophen results in increased expression of GPT protein] |
CTD |
PMID:24685772 PMID:27470132 PMID:31678598 |
|
NCBI chr 8:144,503,068...144,507,172
Ensembl chr 8:144,502,973...144,507,174
|
|
G |
GPX2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of GPX2 mRNA |
CTD |
PMID:21224054 PMID:33629115 |
|
NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746
|
|
G |
GRIA1 |
glutamate ionotropic receptor AMPA type subunit 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of GRIA1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:153,489,615...153,813,869
Ensembl chr 5:153,489,615...153,813,869
|
|
G |
GSR |
glutathione-disulfide reductase |
increases activity |
ISO |
Rifampin results in increased activity of GSR protein |
CTD |
PMID:20848779 |
|
NCBI chr 8:30,678,066...30,727,846
Ensembl chr 8:30,678,066...30,727,846
|
|
G |
GSTA1 |
glutathione S-transferase alpha 1 |
multiple interactions increases expression |
EXP |
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of GSTA1 mRNA; Ketoconazole inhibits the reaction [Rifampin results in increased expression of GSTA1 mRNA] |
CTD |
PMID:16608920 PMID:19118567 PMID:29162470 |
|
NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860
|
|
G |
GSTA7P |
glutathione S-transferase alpha 7, pseudogene |
increases expression |
EXP |
Rifampin results in increased expression of GSTA7P mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:52,739,463...52,745,159
Ensembl chr 6:52,739,590...52,744,656
|
|
G |
GSTM1 |
glutathione S-transferase mu 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein |
CTD |
PMID:21224054 |
|
NCBI chr 1:109,687,817...109,693,745
Ensembl chr 1:109,687,814...109,709,039
|
|
G |
GSTM3 |
glutathione S-transferase mu 3 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 1:109,733,937...109,741,038
Ensembl chr 1:109,733,932...109,741,038
|
|
G |
GSTP1 |
glutathione S-transferase pi 1 |
multiple interactions increases expression |
EXP |
[Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 protein Rifampin results in increased expression of GSTP1 mRNA; Rifampin results in increased expression of GSTP1 protein |
CTD |
PMID:22733800 |
|
NCBI chr11:67,583,812...67,586,653
Ensembl chr11:67,583,742...67,586,656
|
|
G |
GSTT1 |
glutathione S-transferase theta 1 |
multiple interactions |
EXP |
GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide] |
CTD |
PMID:18397238 PMID:20485159 |
|
|
|
G |
GTF2IRD2 |
GTF2I repeat domain containing 2 |
increases expression |
EXP |
Rifampin results in increased expression of GTF2IRD2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:74,796,151...74,851,605
Ensembl chr 7:74,796,151...74,851,605
|
|
G |
GZMB |
granzyme B |
increases secretion |
EXP |
Rifampin results in increased secretion of GZMB protein |
CTD |
PMID:27933861 |
|
NCBI chr14:24,630,954...24,634,190
Ensembl chr14:24,630,954...24,634,267
|
|
G |
HBEGF |
heparin binding EGF like growth factor |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 5:140,332,843...140,346,603
Ensembl chr 5:140,332,843...140,346,603
|
|
G |
HDAC3 |
histone deacetylase 3 |
multiple interactions |
EXP |
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]] |
CTD |
PMID:26883953 |
|
NCBI chr 5:141,620,881...141,636,849
Ensembl chr 5:141,620,876...141,636,849
|
|
G |
HDAC5 |
histone deacetylase 5 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:44,076,753...44,123,641
Ensembl chr17:44,076,746...44,123,702
|
|
G |
HEY1 |
hes related family bHLH transcription factor with YRPW motif 1 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 8:79,764,010...79,767,767
Ensembl chr 8:79,762,371...79,767,857
|
|
G |
HGF |
hepatocyte growth factor |
multiple interactions |
ISO |
HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein] |
CTD |
PMID:23764483 |
|
NCBI chr 7:81,699,010...81,770,047
Ensembl chr 7:81,699,010...81,770,438
|
|
G |
HIF1A |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA |
CTD |
PMID:21127053 |
|
NCBI chr14:61,695,513...61,748,258
Ensembl chr14:61,695,513...61,748,259
|
|
G |
HLA-DMA |
major histocompatibility complex, class II, DM alpha |
increases expression |
EXP |
Rifampin results in increased expression of HLA-DMA mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:32,948,618...32,953,097
Ensembl chr 6:32,948,613...32,969,094
|
|
G |
HLA-DQB1 |
major histocompatibility complex, class II, DQ beta 1 |
affects expression |
EXP |
Rifampin affects the expression of HLA-DQB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:32,659,467...32,666,657
Ensembl chr 6:32,659,467...32,668,383
|
|
G |
HLA-DRB6 |
major histocompatibility complex, class II, DR beta 6 (pseudogene) |
affects expression |
EXP |
Rifampin affects the expression of HLA-DRB6 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:32,552,713...32,560,002
Ensembl chr 6:32,552,713...32,560,022
|
|
G |
HLA-G |
major histocompatibility complex, class I, G |
affects expression |
EXP |
Rifampin affects the expression of HLA-G mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 6:29,826,474...29,831,021
Ensembl chr 6:29,826,967...29,831,125
|
|
G |
HMGN5 |
high mobility group nucleosome binding domain 5 |
increases expression |
EXP |
Rifampin results in increased expression of HMGN5 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:81,113,699...81,201,913
Ensembl chr X:81,113,699...81,201,913
|
|
G |
HMOX1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA dorsomorphin inhibits the reaction [Rifampin results in increased expression of HMOX1 protein] Rifampin results in increased expression of HMOX1 mRNA; Rifampin results in increased expression of HMOX1 protein [arsenite co-treated with Rifampin] results in increased expression of HMOX1 mRNA |
CTD |
PMID:21224054 PMID:22159698 PMID:22258563 PMID:31678598 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HNF4A |
hepatocyte nuclear factor 4 alpha |
multiple interactions |
EXP |
[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein] |
CTD |
PMID:21127053 PMID:21292004 PMID:21764778 PMID:25069801 |
|
NCBI chr20:44,355,699...44,434,596
Ensembl chr20:44,355,700...44,432,845
|
|
G |
HRH1 |
histamine receptor H1 |
increases expression |
EXP |
Rifampin results in increased expression of HRH1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:11,137,238...11,263,557
Ensembl chr 3:11,137,093...11,263,557
|
|
G |
HSPA1L |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 6:31,809,619...31,815,283
Ensembl chr 6:31,809,619...31,815,283
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
ISO EXP |
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] [Rifampin co-treated with Cobicistat] results in increased expression of HSPA5 mRNA Rifampin results in increased expression of HSPA5 mRNA; Rifampin results in increased expression of HSPA5 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] |
CTD |
PMID:24638036 PMID:27470132 PMID:32535746 PMID:33629115 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
|
|
G |
HSPA8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr11:123,057,489...123,062,462
Ensembl chr11:123,057,489...123,063,230
|
|
G |
HSPB1 |
heat shock protein family B (small) member 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 7:76,302,673...76,304,292
Ensembl chr 7:76,302,673...76,304,295
|
|
G |
HSPD1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 2:197,486,584...197,500,274
Ensembl chr 2:197,486,584...197,516,737
|
|
G |
HSPE1 |
heat shock protein family E (Hsp10) member 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 2:197,500,379...197,503,449
Ensembl chr 2:197,500,140...197,503,449
|
|
G |
IFNG |
interferon gamma |
increases secretion |
EXP |
Rifampin results in increased secretion of IFNG protein |
CTD |
PMID:27933861 |
|
NCBI chr12:68,154,768...68,159,740
Ensembl chr12:68,154,768...68,159,740
|
|
G |
IGFBP1 |
insulin like growth factor binding protein 1 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660
|
|
G |
IGFBP3 |
insulin like growth factor binding protein 3 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 7:45,912,245...45,921,272
Ensembl chr 7:45,912,245...45,921,874
|
|
G |
IGFBP4 |
insulin like growth factor binding protein 4 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:40,443,450...40,457,725
Ensembl chr17:40,443,450...40,457,725
|
|
G |
IL10 |
interleukin 10 |
affects expression |
ISO |
Rifampin affects the expression of IL10 protein |
CTD |
PMID:25051504 |
|
NCBI chr 1:206,767,602...206,772,494
Ensembl chr 1:206,767,602...206,774,541
|
|
G |
IL12RB2 |
interleukin 12 receptor subunit beta 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of IL12RB2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:67,307,364...67,398,724
Ensembl chr 1:67,307,364...67,398,724
|
|
G |
IL13 |
interleukin 13 |
increases secretion |
EXP |
Rifampin results in increased secretion of IL13 protein |
CTD |
PMID:27933861 |
|
NCBI chr 5:132,656,522...132,661,110
Ensembl chr 5:132,656,263...132,661,110
|
|
G |
IL18 |
interleukin 18 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr11:112,143,260...112,164,094
Ensembl chr11:112,143,253...112,164,096
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions decreases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; Rifampin inhibits the reaction [Rotenone results in increased expression of and results in increased secretion of IL1B protein]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] Rifampin results in decreased expression of IL1B mRNA; Rifampin results in decreased expression of IL1B protein |
CTD |
PMID:21224054 PMID:25051504 PMID:26086368 PMID:31648047 |
|
NCBI chr 2:112,829,751...112,836,779
Ensembl chr 2:112,829,751...112,836,816
|
|
G |
IL37 |
interleukin 37 |
increases expression |
EXP |
Rifampin results in increased expression of IL37 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:112,911,165...112,918,882
Ensembl chr 2:112,911,165...112,918,882
|
|
G |
IL6 |
interleukin 6 |
decreases expression multiple interactions increases expression |
EXP ISO |
Rifampin results in decreased expression of IL6 protein Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA] Rifampin results in increased expression of IL6 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA |
CTD |
PMID:21224054 PMID:21357946 PMID:25051504 PMID:31648047 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
INO80D |
INO80 complex subunit D |
decreases expression |
EXP |
Rifampin results in decreased expression of INO80D mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:205,993,721...206,086,174
Ensembl chr 2:205,993,721...206,086,303
|
|
G |
INS |
insulin |
multiple interactions |
EXP ISO |
INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA] Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein] |
CTD |
PMID:24204015 PMID:33412187 |
|
NCBI chr11:2,159,779...2,161,209
Ensembl chr11:2,159,779...2,161,221
|
|
G |
INTS6 |
integrator complex subunit 6 |
decreases expression |
EXP |
Rifampin results in decreased expression of INTS6 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr13:51,334,405...51,453,036
Ensembl chr13:51,354,077...51,454,264
|
|
G |
IQCA1 |
IQ motif containing with AAA domain 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of IQCA1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:236,306,685...236,507,476
Ensembl chr 2:236,324,147...236,507,535
|
|
G |
ITGBL1 |
integrin subunit beta like 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of ITGBL1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr13:101,452,675...101,723,106
Ensembl chr13:101,452,593...101,720,856
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
KIRREL3 |
kirre like nephrin family adhesion molecule 3 |
decreases expression |
EXP |
Rifampin results in decreased expression of KIRREL3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr11:126,423,358...127,000,870
Ensembl chr11:126,423,358...127,003,460
|
|
G |
KLF2 |
Kruppel like factor 2 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr19:16,324,826...16,328,685
Ensembl chr19:16,324,826...16,328,685
|
|
G |
KLF5 |
Kruppel like factor 5 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr13:73,054,976...73,077,538
Ensembl chr13:73,054,976...73,077,541
|
|
G |
KLF6 |
Kruppel like factor 6 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:3,775,996...3,785,209
Ensembl chr10:3,775,996...3,785,281
|
|
G |
KLHL23 |
kelch like family member 23 |
decreases expression |
EXP |
Rifampin results in decreased expression of KLHL23 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:169,733,832...169,751,878
Ensembl chr 2:169,694,488...169,776,989
|
|
G |
LDLR |
low density lipoprotein receptor |
increases expression |
ISO |
Rifampin results in increased expression of LDLR mRNA |
CTD |
PMID:27806127 |
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,462...11,133,820
|
|
G |
LEFTY1 |
left-right determination factor 1 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:225,886,282...225,889,146
Ensembl chr 1:225,886,282...225,911,382
|
|
G |
LEP |
leptin |
increases expression |
ISO |
Rifampin results in increased expression of LEP protein |
CTD |
PMID:25051504 |
|
NCBI chr 7:128,241,278...128,257,629
Ensembl chr 7:128,241,278...128,257,629
|
|
G |
LIMS3 |
LIM zinc finger domain containing 3 |
decreases expression |
EXP |
Rifampin results in decreased expression of LIMS3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:109,898,688...109,925,625
Ensembl chr 2:109,898,428...109,925,625
|
|
G |
LINC02898 |
long intergenic non-protein coding RNA 2898 |
decreases expression |
EXP |
Rifampin results in decreased expression of LINC02898 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:41,935,368...41,953,806
Ensembl chr 2:41,935,368...41,956,806
|
|
G |
LL22NC03-63E9.3 |
uncharacterized LOC648691 |
increases expression |
EXP |
Rifampin results in increased expression of LL22NC03-63E9.3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr22:22,559,343...22,566,599
Ensembl chr22:22,559,343...22,566,602
|
|
G |
LTK |
leukocyte receptor tyrosine kinase |
increases expression |
EXP |
Rifampin results in increased expression of LTK mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:41,503,637...41,513,827
Ensembl chr15:41,503,637...41,513,887
|
|
G |
MAFF |
MAF bZIP transcription factor F |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA |
CTD |
PMID:21127053 |
|
NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
decreases metabolic processing increases lipidation multiple interactions |
EXP |
Rifampin results in decreased metabolism of MAP1LC3B protein Rifampin results in increased lipidation of MAP1LC3B protein ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [Rifampin results in increased lipidation of MAP1LC3B protein]; Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:29908302 PMID:31648047 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]]; Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:31648047 |
|
NCBI chr10:48,306,677...48,439,360
Ensembl chr10:48,306,639...48,439,360
|
|
G |
MAPKAPK2 |
MAPK activated protein kinase 2 |
increases phosphorylation |
EXP |
Rifampin results in increased phosphorylation of MAPKAPK2 protein |
CTD |
PMID:21127053 |
|
NCBI chr 1:206,684,905...206,734,281
Ensembl chr 1:206,684,905...206,734,281
|
|
G |
MAPRE3 |
microtubule associated protein RP/EB family member 3 |
increases expression |
EXP |
Rifampin results in increased expression of MAPRE3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:26,970,637...27,027,219
Ensembl chr 2:26,970,637...27,027,219
|
|
G |
MATN2 |
matrilin 2 |
increases expression |
EXP |
Rifampin results in increased expression of MATN2 mRNA |
CTD |
PMID:27177772 |
|
NCBI chr 8:97,869,064...98,036,724
Ensembl chr 8:97,868,840...98,036,724
|
|
G |
MBP |
myelin basic protein |
affects expression |
ISO |
Rifampin affects the expression of MBP mRNA |
CTD |
PMID:22954530 |
|
NCBI chr18:76,978,833...77,133,708
Ensembl chr18:76,978,827...77,133,683
|
|
G |
MCL1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
EXP |
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein |
CTD |
PMID:31629065 |
|
NCBI chr 1:150,574,558...150,579,610
Ensembl chr 1:150,560,895...150,579,738
|
|
G |
MDM2 |
MDM2 proto-oncogene |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr12:68,808,172...68,850,686
Ensembl chr12:68,808,177...68,845,544
|
|
G |
MED1 |
mediator complex subunit 1 |
multiple interactions decreases expression |
EXP |
Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein] Rifampin results in decreased expression of MED1 mRNA |
CTD |
PMID:21292004 PMID:22214767 PMID:24552687 |
|
NCBI chr17:39,404,285...39,451,263
Ensembl chr17:39,404,285...39,451,272
|
|
G |
MINPP1 |
multiple inositol-polyphosphate phosphatase 1 |
increases expression |
EXP |
Rifampin results in increased expression of MINPP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:87,504,893...87,553,461
Ensembl chr10:87,504,875...87,553,461
|
|
G |
MIR143 |
microRNA 143 |
increases expression |
EXP |
Rifampin results in increased expression of MIR143 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:149,428,918...149,429,023
Ensembl chr 5:149,428,918...149,429,023
|
|
G |
MIR145 |
microRNA 145 |
increases expression |
EXP |
Rifampin results in increased expression of MIR145 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:149,430,646...149,430,733
Ensembl chr 5:149,430,646...149,430,733
|
|
G |
MIR148B |
microRNA 148b |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR148B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:54,337,216...54,337,314
Ensembl chr12:54,337,216...54,337,314
|
|
G |
MIR149 |
microRNA 149 |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR149 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:240,456,001...240,456,089
Ensembl chr 2:240,456,001...240,456,089
|
|
G |
MIR15B |
microRNA 15b |
increases expression |
EXP |
Rifampin results in increased expression of MIR15B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:160,404,588...160,404,685
Ensembl chr 3:160,404,588...160,404,685
|
|
G |
MIR192 |
microRNA 192 |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR192 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr11:64,891,137...64,891,246
Ensembl chr11:64,891,137...64,891,246
|
|
G |
MIR197 |
microRNA 197 |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR197 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:109,598,893...109,598,967
Ensembl chr 1:109,598,893...109,598,967
|
|
G |
MIR200A |
microRNA 200a |
increases expression |
EXP |
Rifampin results in increased expression of MIR200A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:1,167,863...1,167,952
Ensembl chr 1:1,167,863...1,167,952
|
|
G |
MIR202 |
microRNA 202 |
increases expression |
EXP |
Rifampin results in increased expression of MIR202 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:133,247,511...133,247,620
Ensembl chr10:133,247,511...133,247,620
|
|
G |
MIR204 |
microRNA 204 |
increases expression |
EXP |
Rifampin results in increased expression of MIR204 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:70,809,975...70,810,084
Ensembl chr 9:70,809,975...70,810,084
|
|
G |
MIR20B |
microRNA 20b |
increases expression |
EXP |
Rifampin results in increased expression of MIR20B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:134,169,809...134,169,877
Ensembl chr X:134,169,809...134,169,877
|
|
G |
MIR21 |
microRNA 21 |
increases expression |
EXP |
Rifampin results in increased expression of MIR21 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:59,841,266...59,841,337
Ensembl chr17:59,841,266...59,841,337
|
|
G |
MIR212 |
microRNA 212 |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR212 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:2,050,271...2,050,380
Ensembl chr17:2,050,271...2,050,380
|
|
G |
MIR215 |
microRNA 215 |
increases expression |
EXP |
Rifampin results in increased expression of MIR215 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:220,117,853...220,117,962
Ensembl chr 1:220,117,853...220,117,962
|
|
G |
MIR22 |
microRNA 22 |
increases expression |
EXP |
Rifampin results in increased expression of MIR22 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:1,713,903...1,713,987
Ensembl chr17:1,713,903...1,713,987
|
|
G |
MIR26B |
microRNA 26b |
increases expression |
EXP |
Rifampin results in increased expression of MIR26B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:218,402,646...218,402,722
Ensembl chr 2:218,402,646...218,402,722
|
|
G |
MIR296 |
microRNA 296 |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR296 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr20:58,817,615...58,817,694
Ensembl chr20:58,817,615...58,817,694
|
|
G |
MIR29A |
microRNA 29a |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR29A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:130,876,747...130,876,810
Ensembl chr 7:130,876,747...130,876,810
|
|
G |
MIR31 |
microRNA 31 |
increases expression |
EXP |
Rifampin results in increased expression of MIR31 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:21,512,115...21,512,185
Ensembl chr 9:21,512,115...21,512,185
|
|
G |
MIR328 |
microRNA 328 |
increases expression |
EXP |
Rifampin results in increased expression of MIR328 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr16:67,202,321...67,202,395
Ensembl chr16:67,202,321...67,202,395
|
|
G |
MIR340 |
microRNA 340 |
increases expression |
EXP |
Rifampin results in increased expression of MIR340 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:180,015,303...180,015,397
Ensembl chr 5:180,015,303...180,015,397
|
|
G |
MIR34A |
microRNA 34a |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR34A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:9,151,668...9,151,777
Ensembl chr 1:9,151,668...9,151,777
|
|
G |
MIR362 |
microRNA 362 |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR362 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:50,008,964...50,009,028
Ensembl chr X:50,008,964...50,009,028
|
|
G |
MIR374B |
microRNA 374b |
increases expression |
EXP |
Rifampin results in increased expression of MIR374B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:74,218,547...74,218,618
Ensembl chr X:74,218,547...74,218,618
|
|
G |
MIR532 |
microRNA 532 |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR532 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:50,003,148...50,003,238
Ensembl chr X:50,003,148...50,003,238
|
|
G |
MIR539 |
microRNA 539 |
increases expression |
EXP |
Rifampin results in increased expression of MIR539 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr14:101,047,321...101,047,398
Ensembl chr14:101,047,321...101,047,398
|
|
G |
MIR576 |
microRNA 576 |
increases expression |
EXP |
Rifampin results in increased expression of MIR576 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:109,488,698...109,488,795
Ensembl chr 4:109,488,698...109,488,795
|
|
G |
MIR590 |
microRNA 590 |
increases expression |
EXP |
Rifampin results in increased expression of MIR590 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:74,191,198...74,191,294
Ensembl chr 7:74,191,198...74,191,294
|
|
G |
MIR618 |
microRNA 618 |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR618 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:80,935,736...80,935,833
Ensembl chr12:80,935,736...80,935,833
|
|
G |
MIR628 |
microRNA 628 |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR628 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:55,372,940...55,373,034
Ensembl chr15:55,372,940...55,373,034
|
|
G |
MIR652 |
microRNA 652 |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR652 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:110,055,329...110,055,426
Ensembl chr X:110,055,329...110,055,426
|
|
G |
MIR874 |
microRNA 874 |
decreases expression |
EXP |
Rifampin results in decreased expression of MIR874 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:137,647,572...137,647,649
Ensembl chr 5:137,647,572...137,647,649
|
|
G |
MIR95 |
microRNA 95 |
increases expression |
EXP |
Rifampin results in increased expression of MIR95 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:8,005,301...8,005,381
Ensembl chr 4:8,005,301...8,005,381
|
|
G |
MIRLET7E |
microRNA let-7e |
increases expression |
EXP |
Rifampin results in increased expression of MIRLET7E mRNA |
CTD |
PMID:24552687 |
|
NCBI chr19:51,692,786...51,692,864
Ensembl chr19:51,692,786...51,692,864
|
|
G |
MKI67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein |
CTD |
PMID:21224054 |
|
NCBI chr10:128,096,659...128,126,423
Ensembl chr10:128,096,659...128,126,423
|
|
G |
MMP3 |
matrix metallopeptidase 3 |
decreases secretion |
EXP |
Rifampin results in decreased secretion of MMP3 protein |
CTD |
PMID:24890593 |
|
NCBI chr11:102,835,801...102,843,609
Ensembl chr11:102,835,801...102,843,609
|
|
G |
MPO |
myeloperoxidase |
multiple interactions |
ISO |
Rifampin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:24101390 |
|
NCBI chr17:58,269,855...58,280,935
Ensembl chr17:58,269,855...58,280,935
|
|
G |
MR1 |
major histocompatibility complex, class I-related |
affects expression |
EXP |
Rifampin affects the expression of MR1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr 1:181,033,387...181,061,938
Ensembl chr 1:181,033,374...181,061,938
|
|
G |
MTTP |
microsomal triglyceride transfer protein |
decreases expression |
EXP |
Rifampin results in decreased expression of MTTP mRNA |
CTD |
PMID:32535746 |
|
NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,564,081...99,623,997
|
|
G |
MYH16 |
myosin heavy chain 16 pseudogene |
decreases expression |
EXP |
Rifampin results in decreased expression of MYH16 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:99,238,829...99,311,128
Ensembl chr 7:99,238,829...99,311,130
|
|
G |
MYH6 |
myosin heavy chain 6 |
increases expression |
EXP |
Rifampin results in increased expression of MYH6 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr14:23,381,987...23,408,273
Ensembl chr14:23,381,982...23,408,273
|
|
G |
NAF1 |
nuclear assembly factor 1 ribonucleoprotein |
decreases expression |
EXP |
Rifampin results in decreased expression of NAF1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:163,103,929...163,166,890
Ensembl chr 4:163,110,073...163,166,890
|
|
G |
NAP1L5 |
nucleosome assembly protein 1 like 5 |
increases expression |
EXP |
Rifampin results in increased expression of NAP1L5 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:88,695,913...88,697,829
Ensembl chr 4:88,695,913...88,697,829
|
|
G |
NCOA1 |
nuclear receptor coactivator 1 |
multiple interactions |
EXP |
Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Miconazole promotes the reaction [Rifampin results in increased expression of NCOA1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein] |
CTD |
PMID:11581012 PMID:12072427 PMID:16819505 PMID:17088262 PMID:17438109 PMID:17998298 PMID:21115105 PMID:21292004 PMID:22214767 PMID:23525103 PMID:25313206 PMID:26920453 PMID:27871908 PMID:28289823 PMID:29356861 More...
|
|
NCBI chr 2:24,491,254...24,770,702
Ensembl chr 2:24,491,254...24,770,702
|
|
G |
NCOA2 |
nuclear receptor coactivator 2 |
multiple interactions |
EXP |
Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein] |
CTD |
PMID:21292004 |
|
NCBI chr 8:70,109,782...70,456,446
Ensembl chr 8:70,109,782...70,403,808
|
|
G |
NCOA6 |
nuclear receptor coactivator 6 |
multiple interactions |
EXP |
NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein] |
CTD |
PMID:21292004 |
|
NCBI chr20:34,714,774...34,825,651
Ensembl chr20:34,689,097...34,825,651
|
|
G |
NCOR1 |
nuclear receptor corepressor 1 |
multiple interactions |
EXP |
Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein] |
CTD |
PMID:22214767 |
|
NCBI chr17:16,029,157...16,215,534
Ensembl chr17:16,029,157...16,218,185
|
|
G |
NCOR2 |
nuclear receptor corepressor 2 |
multiple interactions |
EXP |
[NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein] |
CTD |
PMID:12072427 PMID:22214767 PMID:25313206 PMID:26883953 PMID:28289823 PMID:29356861 More...
|
|
NCBI chr12:124,324,415...124,567,612
Ensembl chr12:124,324,415...124,567,589
|
|
G |
NFE2L2 |
NFE2 like bZIP transcription factor 2 |
increases expression decreases activity multiple interactions |
EXP ISO |
Rifampin results in increased expression of NFE2L2 protein Rifampin results in decreased activity of NFE2L2 protein Rifampin inhibits the reaction [arsenite results in increased activity of NFE2L2 protein] |
CTD |
PMID:31678598 PMID:33412187 |
|
NCBI chr 2:177,230,303...177,264,727
Ensembl chr 2:177,227,595...177,392,697
|
|
G |
NFYA |
nuclear transcription factor Y subunit alpha |
decreases expression |
EXP |
Rifampin results in decreased expression of NFYA mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:41,072,974...41,102,403
Ensembl chr 6:41,072,974...41,102,403
|
|
G |
NKAPP1 |
NFKB activating protein pseudogene 1 |
increases expression |
EXP |
Rifampin results in increased expression of NKAPP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:120,236,452...120,245,267
Ensembl chr X:120,120,953...120,245,273
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [Rotenone results in increased expression of NLRP3 protein] |
CTD |
PMID:26086368 |
|
NCBI chr 1:247,416,077...247,448,817
Ensembl chr 1:247,416,156...247,449,108
|
|
G |
NOS2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA Rifampin results in increased expression of NOS2 mRNA |
CTD |
PMID:21224054 PMID:24552687 |
|
NCBI chr17:27,756,766...27,800,529
Ensembl chr17:27,756,766...27,800,529
|
|
G |
NPAS1 |
neuronal PAS domain protein 1 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr19:47,019,837...47,045,775
Ensembl chr19:47,019,837...47,045,775
|
|
G |
NPPB |
natriuretic peptide B |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:11,857,464...11,858,945
Ensembl chr 1:11,857,464...11,858,945
|
|
G |
NR0B2 |
nuclear receptor subfamily 0 group B member 2 |
increases expression decreases expression |
EXP |
Rifampin results in increased expression of NR0B2 mRNA Rifampin results in decreased expression of NR0B2 mRNA |
CTD |
PMID:15670600 PMID:34689256 |
|
NCBI chr 1:26,911,489...26,913,975
Ensembl chr 1:26,911,489...26,913,975
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
multiple interactions |
EXP |
NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:23732298 |
|
NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
affects response to substance decreases acetylation affects localization increases response to substance increases activity decreases response to substance multiple interactions increases expression increases localization affects binding |
EXP ISO |
NR1I2 protein affects the susceptibility to Rifampin Rifampin results in decreased acetylation of NR1I2 protein Rifampin affects the localization of NR1I2 protein NR1I2 protein results in increased susceptibility to Rifampin [Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of NR1I2 protein NR1I2 protein mutant form results in decreased susceptibility to Rifampin 1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [fexofenadine co-treated with Rifampin] results in increased activity of NR1I2 protein; [Ketoconazole co-treated with Rifampin] results in increased activity of NR1I2 protein; [Loperamide co-treated with Rifampin] results in increased activity of NR1I2 protein; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I2 protein; [Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Camptothecin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; caraway oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Clove Oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; coriander oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Doxorubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Epirubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Fluconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; hydroxyitraconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Itraconazole promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; jasmine oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin binds to and results in increased activity of NR1I2 protein]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; lemongrass oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Miconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of amprenavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Midazolam]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Nelfinavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Saquinavir]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased abundance of Lipids]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Oils, Volatile inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Oils, Volatile promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; oxiconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pazopanib inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin binds to and results in increased activity of NR1I2 protein; Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin inhibits the reaction [oxiconazole results in increased expression of NR1I2 mRNA]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin inhibits the reaction [trichostatin A results in increased acetylation of NR1I2 protein]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; sulforaphane inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; trichostatin A affects the reaction [Rifampin affects the localization of NR1I2 protein] Rifampin results in increased expression of NR1I2 mRNA; Rifampin results in increased expression of NR1I2 protein Rifampin results in increased localization of NR1I2 protein [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased localization of NR1I2 protein]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA] Rifampin binds to NR1I2 gene mutant form [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CES2A mRNA; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CYP3A11 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; NR1I2 affects the reaction [Rifampin results in increased activity of CYP3A4 protein]; Rifampin affects the localization of and results in increased activity of NR1I2 protein; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] [Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter; Rifampin binds to NR1I2 protein |
CTD |
PMID:11581012 PMID:12065438 PMID:12072427 PMID:12370413 PMID:12417264 PMID:12695340 PMID:12695351 PMID:14570758 PMID:14600250 PMID:14636322 PMID:14977870 PMID:15489543 PMID:15548381 PMID:15630458 PMID:15670600 PMID:15705662 PMID:15802384 PMID:15833926 PMID:15849716 PMID:15864135 PMID:15883047 PMID:15885729 PMID:15933212 PMID:16267138 PMID:16565514 PMID:16608920 PMID:16632523 PMID:16819505 PMID:16857725 PMID:17003103 PMID:17041008 PMID:17088262 PMID:17438109 PMID:17696253 PMID:17936928 PMID:17998298 PMID:18098064 PMID:18180267 PMID:18692084 PMID:18799805 PMID:19249324 PMID:19647009 PMID:19889628 PMID:20041327 PMID:20079722 PMID:20143881 PMID:20361990 PMID:20624464 PMID:20869355 PMID:21115097 PMID:21115105 PMID:21127053 PMID:21227907 PMID:21292004 PMID:21315811 PMID:21402137 PMID:21641981 PMID:21742782 PMID:21764778 PMID:21924250 PMID:22093699 PMID:22101211 PMID:22159698 PMID:22206814 PMID:22214767 PMID:22310298 PMID:22310326 PMID:22314385 PMID:22467028 PMID:22664347 PMID:22687401 PMID:22733800 PMID:22982774 PMID:23439660 PMID:23525103 PMID:23707768 PMID:23732298 PMID:23845848 PMID:23850985 PMID:23899473 PMID:24204015 PMID:25069801 PMID:25313206 PMID:25455453 PMID:25472953 PMID:25542144 PMID:25616597 PMID:25680588 PMID:25835148 PMID:26187274 PMID:26196221 PMID:26238175 PMID:26341324 PMID:26616219 PMID:26778350 PMID:26883953 PMID:26920453 PMID:27177772 PMID:27180241 PMID:27806127 PMID:27871908 PMID:27918128 PMID:28115241 PMID:28259787 PMID:28289823 PMID:28428138 PMID:28496040 PMID:28887089 PMID:29356861 PMID:29933105 PMID:30071242 PMID:30394306 PMID:30582956 PMID:31233785 PMID:31472229 PMID:32092453 PMID:33002526 PMID:33629115 More...
|
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
increases expression multiple interactions |
ISO EXP |
Rifampin results in increased expression of NR1I3 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein Rifampin results in increased expression of NR1I3 mRNA; Rifampin results in increased expression of NR1I3 protein [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 protein |
CTD |
PMID:19118567 PMID:22733800 PMID:25835148 |
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
G |
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
multiple interactions increases expression |
EXP |
Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] Rifampin results in increased expression of NR3C1 mRNA |
CTD |
PMID:10219967 PMID:12673034 PMID:12695351 |
|
NCBI chr 5:143,277,931...143,435,512
Ensembl chr 5:143,277,931...143,435,512
|
|
G |
NRL |
neural retina leucine zipper |
increases expression |
EXP |
Rifampin results in increased expression of NRL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr14:24,078,662...24,114,949
Ensembl chr14:24,078,662...24,115,010
|
|
G |
OBSL1 |
obscurin like cytoskeletal adaptor 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of OBSL1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:219,547,206...219,571,539
Ensembl chr 2:219,550,728...219,571,859
|
|
G |
OCLN |
occludin |
affects localization |
ISO |
Rifampin affects the localization of OCLN protein |
CTD |
PMID:19577586 |
|
NCBI chr 5:69,492,547...69,558,104
Ensembl chr 5:69,492,292...69,558,104
|
|
G |
OR4A47 |
olfactory receptor family 4 subfamily A member 47 |
decreases expression |
EXP |
Rifampin results in decreased expression of OR4A47 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr11:48,488,793...48,489,722
Ensembl chr11:48,488,793...48,489,722
|
|
G |
P4HB |
prolyl 4-hydroxylase subunit beta |
decreases expression |
EXP |
Rifampin results in decreased expression of P4HB mRNA |
CTD |
PMID:32535746 |
|
NCBI chr17:81,843,166...81,860,535
Ensembl chr17:81,843,159...81,860,856
|
|
G |
PARP1 |
poly(ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein] |
CTD |
PMID:31678598 |
|
NCBI chr 1:226,360,691...226,408,093
Ensembl chr 1:226,360,210...226,408,154
|
|
G |
PAX7 |
paired box 7 |
decreases expression |
EXP |
Rifampin results in decreased expression of PAX7 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:18,630,846...18,748,866
Ensembl chr 1:18,630,846...18,748,866
|
|
G |
PCK1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions increases expression |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA] Rifampin results in increased expression of PCK1 mRNA |
CTD |
PMID:24204015 PMID:34689256 |
|
NCBI chr20:57,561,110...57,568,121
Ensembl chr20:57,561,080...57,568,121
|
|
G |
PCLAF |
PCNA clamp associated factor |
increases expression |
EXP |
Rifampin results in increased expression of PCLAF mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:64,364,304...64,387,687
Ensembl chr15:64,364,304...64,387,687
|
|
G |
PDAP1 |
PDGFA associated protein 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of PDAP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:99,394,673...99,408,597
Ensembl chr 7:99,392,048...99,408,597
|
|
G |
PDE4D |
phosphodiesterase 4D |
decreases expression |
EXP |
Rifampin results in decreased expression of PDE4D mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:58,969,038...60,522,128
Ensembl chr 5:58,969,038...60,522,120
|
|
G |
PEG3 |
paternally expressed 3 |
increases expression |
EXP |
Rifampin results in increased expression of PEG3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr19:56,810,082...56,840,726
Ensembl chr19:56,810,077...56,840,728
|
|
G |
PIAS1 |
protein inhibitor of activated STAT 1 |
multiple interactions |
EXP |
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]] |
CTD |
PMID:26883953 |
|
NCBI chr15:68,054,315...68,193,847
Ensembl chr15:68,054,309...68,198,603
|
|
G |
PILRA |
paired immunoglobin like type 2 receptor alpha |
decreases expression |
EXP |
Rifampin results in decreased expression of PILRA mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:100,371,291...100,400,096
Ensembl chr 7:100,367,530...100,400,096
|
|
G |
PIP4K2A |
phosphatidylinositol-5-phosphate 4-kinase type 2 alpha |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:22,534,854...22,714,578
Ensembl chr10:22,534,854...22,714,578
|
|
G |
PKD2L1 |
polycystin 2 like 1, transient receptor potential cation channel |
decreases expression |
EXP |
Rifampin results in decreased expression of PKD2L1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:100,288,149...100,330,228
Ensembl chr10:100,288,149...100,330,264
|
|
G |
PKLR |
pyruvate kinase L/R |
increases expression |
EXP |
Rifampin results in increased expression of PKLR mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:155,289,293...155,308,654
Ensembl chr 1:155,289,293...155,301,438
|
|
G |
PLAAT2 |
phospholipase A and acyltransferase 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of PLAAT2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr11:63,552,770...63,565,070
Ensembl chr11:63,552,770...63,563,379
|
|
G |
PLAT |
plasminogen activator, tissue type |
decreases expression |
EXP |
Rifampin results in decreased expression of PLAT mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:42,174,718...42,207,565
Ensembl chr 8:42,174,718...42,207,709
|
|
G |
PON1 |
paraoxonase 1 |
increases expression |
EXP |
Rifampin results in increased expression of PON1 mRNA |
CTD |
PMID:26434531 |
|
NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532
|
|
G |
POR |
cytochrome p450 oxidoreductase |
increases activity |
ISO |
Rifampin results in increased activity of POR protein |
CTD |
PMID:12051692 |
|
NCBI chr 7:75,915,155...75,986,855
Ensembl chr 7:75,899,200...75,986,855
|
|
G |
POU2F1 |
POU class 2 homeobox 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of POU2F1 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 1:167,220,885...167,427,345
Ensembl chr 1:167,220,876...167,427,345
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA |
CTD |
PMID:16292757 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
multiple interactions increases expression |
ISO |
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA alternative form; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]; Rifampin results in increased expression of and affects the localization of PPARG protein Rifampin results in increased expression of PPARG mRNA |
CTD |
PMID:27806127 PMID:33412187 |
|
NCBI chr 3:12,287,368...12,434,344
Ensembl chr 3:12,287,368...12,434,356
|
|
G |
PPARGC1A |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [PPARGC1A protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein] |
CTD |
PMID:16857725 PMID:21292004 PMID:25069801 |
|
NCBI chr 4:23,792,021...24,472,905
Ensembl chr 4:23,755,041...23,904,089
|
|
G |
PRKDC |
protein kinase, DNA-activated, catalytic subunit |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2B9 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A14 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A4 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA; PRKDC gene mutant form results in increased susceptibility to [Rifampin co-treated with Phenytoin co-treated with Monocrotaline] |
CTD |
PMID:21224054 |
|
NCBI chr 8:47,773,111...47,960,136
Ensembl chr 8:47,773,111...47,960,178
|
|
G |
PRMT1 |
protein arginine methyltransferase 1 |
multiple interactions |
EXP |
PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:31877331 |
|
NCBI chr19:49,676,153...49,688,447
Ensembl chr19:49,675,786...49,689,029
|
|
G |
PRUNE1 |
prune exopolyphosphatase 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of PRUNE1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:151,008,449...151,035,713
Ensembl chr 1:151,008,420...151,035,713
|
|
G |
PSIP1 |
PC4 and SFRS1 interacting protein 1 |
increases expression |
EXP |
Rifampin results in increased expression of PSIP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:15,464,066...15,510,970
Ensembl chr 9:15,464,066...15,510,995
|
|
G |
PSMC3IP |
PSMC3 interacting protein |
increases expression |
EXP |
Rifampin results in increased expression of PSMC3IP mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:42,572,310...42,577,831
Ensembl chr17:42,572,310...42,577,831
|
|
G |
RAD50 |
RAD50 double strand break repair protein |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 5:132,556,977...132,646,349
Ensembl chr 5:132,556,019...132,646,349
|
|
G |
RGPD6 |
RANBP2 like and GRIP domain containing 6 |
decreases expression |
EXP |
Rifampin results in decreased expression of RGPD6 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:110,513,802...110,611,056
Ensembl chr 2:110,513,802...110,610,840
|
|
G |
RIC8B |
RIC8 guanine nucleotide exchange factor B |
decreases expression |
EXP |
Rifampin results in decreased expression of RIC8B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:106,774,682...106,889,316
Ensembl chr12:106,774,621...106,889,316
|
|
G |
RNA5-8SN4 |
RNA, 5.8S ribosomal N4 |
decreases expression |
EXP |
Rifampin results in decreased expression of RNA5-8SN4 mRNA |
CTD |
PMID:24552687 |
|
|
|
G |
RNF6 |
ring finger protein 6 |
decreases expression |
EXP |
Rifampin results in decreased expression of RNF6 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr13:26,132,115...26,223,085
Ensembl chr13:26,132,115...26,222,314
|
|
G |
RRAGB |
Ras related GTP binding B |
decreases expression |
EXP |
Rifampin results in decreased expression of RRAGB mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:55,717,749...55,758,774
Ensembl chr X:55,717,749...55,758,774
|
|
G |
RSPO3 |
R-spondin 3 |
decreases expression |
EXP |
Rifampin results in decreased expression of RSPO3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:127,118,671...127,199,481
Ensembl chr 6:127,118,671...127,199,481
|
|
G |
RXRA |
retinoid X receptor alpha |
multiple interactions |
EXP ISO |
1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA] [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] |
CTD |
PMID:12370413 PMID:16292757 PMID:16632523 PMID:21315811 PMID:25069801 |
|
NCBI chr 9:134,326,455...134,440,585
Ensembl chr 9:134,317,098...134,440,585
|
|
G |
SCARB1 |
scavenger receptor class B member 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of SCARB1 mRNA; Rifampin results in decreased expression of SCARB1 protein |
CTD |
PMID:15883047 |
|
NCBI chr12:124,776,856...124,863,864
Ensembl chr12:124,776,856...124,882,668
|
|
G |
SEMA3F-AS1 |
SEMA3F antisense RNA 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of SEMA3F-AS1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:50,116,022...50,156,085
Ensembl chr 3:50,116,022...50,156,085
|
|
G |
SEPTIN8 |
septin 8 |
increases expression |
EXP |
Rifampin results in increased expression of SEPTIN8 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:132,750,819...132,780,083
Ensembl chr 5:132,750,819...132,807,241
|
|
G |
SERPINA4 |
serpin family A member 4 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr14:94,561,442...94,569,906
Ensembl chr14:94,561,442...94,569,913
|
|
G |
SERPINB1 |
serpin family B member 1 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 6:2,832,332...2,841,863
Ensembl chr 6:2,832,332...2,841,959
|
|
G |
SERPINB8 |
serpin family B member 8 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr18:63,970,081...64,019,779
Ensembl chr18:63,970,029...64,019,779
|
|
G |
SERPINB9 |
serpin family B member 9 |
multiple interactions increases expression |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA Rifampin results in increased expression of SERPINB9 mRNA |
CTD |
PMID:21127053 PMID:24552687 |
|
NCBI chr 6:2,887,270...2,903,309
Ensembl chr 6:2,887,270...2,903,309
|
|
G |
SERPINE1 |
serpin family E member 1 |
multiple interactions |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:21127053 PMID:21224054 |
|
NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
|
|
G |
SFXN1 |
sideroflexin 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of SFXN1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:175,478,560...175,529,742
Ensembl chr 5:175,477,062...175,529,742
|
|
G |
SGK2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions increases expression |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA] Rifampin results in increased expression of SGK2 mRNA |
CTD |
PMID:21127053 PMID:24204015 |
|
NCBI chr20:43,559,027...43,585,627
Ensembl chr20:43,558,968...43,588,237
|
|
G |
SIK2 |
salt inducible kinase 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of SIK2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr11:111,602,449...111,730,855
Ensembl chr11:111,602,449...111,730,855
|
|
G |
SLC10A1 |
solute carrier family 10 member 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
|
|
G |
SLC13A5 |
solute carrier family 13 member 5 |
increases expression |
EXP |
Rifampin results in increased expression of SLC13A5 mRNA; Rifampin results in increased expression of SLC13A5 protein |
CTD |
PMID:25628225 PMID:27199754 |
|
NCBI chr17:6,684,719...6,713,369
Ensembl chr17:6,684,719...6,713,377
|
|
G |
SLC15A1 |
solute carrier family 15 member 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC15A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr13:98,683,801...98,752,672
Ensembl chr13:98,683,801...98,752,672
|
|
G |
SLC16A12 |
solute carrier family 16 member 12 |
increases expression decreases expression |
EXP |
Rifampin results in increased expression of SLC16A12 mRNA Rifampin results in decreased expression of SLC16A12 mRNA |
CTD |
PMID:24552687 PMID:27199754 |
|
NCBI chr10:89,430,299...89,556,704
Ensembl chr10:89,430,299...89,556,641
|
|
G |
SLC17A1 |
solute carrier family 17 member 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC17A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 6:25,723,743...25,832,052
Ensembl chr 6:25,782,915...25,832,052
|
|
G |
SLC1A2 |
solute carrier family 1 member 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC1A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr11:35,251,205...35,420,507
Ensembl chr11:35,251,205...35,420,063
|
|
G |
SLC20A2 |
solute carrier family 20 member 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC20A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 8:42,416,475...42,541,954
Ensembl chr 8:42,416,475...42,541,926
|
|
G |
SLC22A1 |
solute carrier family 22 member 1 |
multiple interactions decreases expression |
EXP |
[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA] Rifampin results in decreased expression of SLC22A1 mRNA; Rifampin results in decreased expression of SLC22A1 protein |
CTD |
PMID:26920453 PMID:27199754 |
|
NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718
|
|
G |
SLC22A7 |
solute carrier family 22 member 7 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC22A7 mRNA |
CTD |
PMID:16837569 PMID:27199754 |
|
NCBI chr 6:43,295,714...43,305,538
Ensembl chr 6:43,295,694...43,305,538
|
|
G |
SLC22A9 |
solute carrier family 22 member 9 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC22A9 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr11:63,369,785...63,410,294
Ensembl chr11:63,369,785...63,410,294
|
|
G |
SLC23A2 |
solute carrier family 23 member 2 |
increases expression |
EXP |
Rifampin results in increased expression of SLC23A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr20:4,852,358...5,010,313
Ensembl chr20:4,852,356...5,010,293
|
|
G |
SLC23A3 |
solute carrier family 23 member 3 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC23A3 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 2:219,161,465...219,170,029
Ensembl chr 2:219,161,465...219,170,095
|
|
G |
SLC25A22 |
solute carrier family 25 member 22 |
increases expression |
EXP |
Rifampin results in increased expression of SLC25A22 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr11:790,475...798,281
Ensembl chr11:790,475...798,281
|
|
G |
SLC25A34 |
solute carrier family 25 member 34 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC25A34 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:15,736,258...15,741,392
Ensembl chr 1:15,736,258...15,741,392
|
|
G |
SLC25A40 |
solute carrier family 25 member 40 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC25A40 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:87,833,568...87,876,360
Ensembl chr 7:87,833,568...87,876,360
|
|
G |
SLC26A2 |
solute carrier family 26 member 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC26A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 5:149,960,758...149,987,400
Ensembl chr 5:149,960,758...149,993,455
|
|
G |
SLC26A4 |
solute carrier family 26 member 4 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC26A4 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 7:107,660,828...107,717,809
Ensembl chr 7:107,660,828...107,717,809
|
|
G |
SLC27A1 |
solute carrier family 27 member 1 |
increases expression |
ISO |
Rifampin results in increased expression of SLC27A1 mRNA |
CTD |
PMID:27806127 |
|
NCBI chr19:17,468,767...17,506,168
Ensembl chr19:17,468,769...17,506,168
|
|
G |
SLC27A2 |
solute carrier family 27 member 2 |
increases expression |
EXP |
Rifampin results in increased expression of SLC27A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr15:50,182,196...50,236,385
Ensembl chr15:50,182,196...50,236,385
|
|
G |
SLC27A3 |
solute carrier family 27 member 3 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC27A3 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:153,775,407...153,780,157
Ensembl chr 1:153,774,354...153,780,157
|
|
G |
SLC27A5 |
solute carrier family 27 member 5 |
increases expression |
EXP |
Rifampin results in increased expression of SLC27A5 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr19:58,498,333...58,511,992
Ensembl chr19:58,479,512...58,512,413
|
|
G |
SLC29A1 |
solute carrier family 29 member 1 (Augustine blood group) |
increases expression |
EXP |
Rifampin results in increased expression of SLC29A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 6:44,219,615...44,234,142
Ensembl chr 6:44,219,553...44,234,142
|
|
G |
SLC29A4 |
solute carrier family 29 member 4 |
increases expression |
EXP |
Rifampin results in increased expression of SLC29A4 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 7:5,282,943...5,306,912
Ensembl chr 7:5,274,369...5,306,912
|
|
G |
SLC2A12 |
solute carrier family 2 member 12 |
increases expression |
EXP |
Rifampin results in increased expression of SLC2A12 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 6:133,987,581...134,052,624
Ensembl chr 6:133,987,581...134,052,624
|
|
G |
SLC2A2 |
solute carrier family 2 member 2 |
multiple interactions decreases expression |
EXP |
NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein] Rifampin results in decreased expression of SLC2A2 mRNA; Rifampin results in decreased expression of SLC2A2 protein |
CTD |
PMID:26616219 PMID:27199754 PMID:34689256 |
|
NCBI chr 3:170,996,347...171,026,720
Ensembl chr 3:170,996,347...171,026,743
|
|
G |
SLC30A10 |
solute carrier family 30 member 10 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC30A10 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:219,910,445...219,959,098
Ensembl chr 1:219,685,427...219,959,018
|
|
G |
SLC38A2 |
solute carrier family 38 member 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC38A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr12:46,358,188...46,372,773
Ensembl chr12:46,358,188...46,372,773
|
|
G |
SLC3A1 |
solute carrier family 3 member 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of SLC3A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 2:44,275,480...44,322,437
Ensembl chr 2:44,275,458...44,321,494
|
|
G |
SLC46A3 |
solute carrier family 46 member 3 |
increases expression |
EXP |
Rifampin results in increased expression of SLC46A3 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr13:28,700,080...28,718,970
Ensembl chr13:28,700,064...28,718,970
|
|
G |
SLC47A1 |
solute carrier family 47 member 1 |
increases expression |
EXP |
Rifampin results in increased expression of SLC47A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr17:19,533,854...19,579,034
Ensembl chr17:19,495,385...19,579,034
|
|
G |
SLC51A |
solute carrier family 51 subunit alpha |
increases expression |
EXP |
Rifampin results in increased expression of SLC51A mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
|
|
G |
SLC51B |
solute carrier family 51 subunit beta |
increases expression |
EXP |
Rifampin results in increased expression of SLC51B mRNA |
CTD |
PMID:27199754 |
|
NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
|
|
G |
SLC5A11 |
solute carrier family 5 member 11 |
increases expression |
EXP |
Rifampin results in increased expression of SLC5A11 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr16:24,845,963...24,911,626
Ensembl chr16:24,845,841...24,911,628
|
|
G |
SLC5A12 |
solute carrier family 5 member 12 |
increases expression |
EXP |
Rifampin results in increased expression of SLC5A12 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr11:26,667,020...26,723,389
Ensembl chr11:26,667,020...26,723,427
|
|
G |
SLC6A12 |
solute carrier family 6 member 12 |
increases expression |
EXP |
Rifampin results in increased expression of SLC6A12 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr12:183,848...214,157
Ensembl chr12:190,077...214,570
|
|
G |
SLC6A20 |
solute carrier family 6 member 20 |
increases expression |
EXP |
Rifampin results in increased expression of SLC6A20 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:45,755,449...45,796,536
Ensembl chr 3:45,755,449...45,796,536
|
|
G |
SLC6A9 |
solute carrier family 6 member 9 |
increases expression |
EXP |
Rifampin results in increased expression of SLC6A9 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:43,996,483...44,031,462
Ensembl chr 1:43,991,500...44,031,467
|
|
G |
SLC9A8 |
solute carrier family 9 member A8 |
increases expression |
EXP |
Rifampin results in increased expression of SLC9A8 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr20:49,812,828...49,892,242
Ensembl chr20:49,812,713...49,892,242
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
decreases activity multiple interactions |
ISO |
Rifampin results in decreased activity of SLCO1A4 protein Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin] |
CTD |
PMID:11883641 |
|
NCBI chr12:21,264,600...21,419,634
Ensembl chr12:21,264,600...21,419,594
|
|
G |
SLCO1B1 |
solute carrier organic anion transporter family member 1B1 |
affects uptake decreases activity multiple interactions increases expression |
EXP |
SLCO1B1 protein affects the uptake of Rifampin Rifampin results in decreased activity of SLCO1B1 protein [Rifampin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Fluvastatin; Rifampin inhibits the reaction [SLCO1B1 protein results in increased import of estradiol-17 beta-glucuronide]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased import of Taurocholic Acid]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of and results in increased susceptibility to cerivastatin]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of and results in increased susceptibility to cyanoginosin LR]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Fluvastatin]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of and results in increased susceptibility to pitavastatin]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Pravastatin]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of and results in increased susceptibility to Rosuvastatin Calcium]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of estradiol-17 beta-glucuronide]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of estrone sulfate]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of Sulfobromophthalein]; Rifampin inhibits the reaction [SLCO1B1 protein results in increased uptake of Ursodeoxycholic Acid metabolite] Rifampin results in increased expression of SLCO1B1 mRNA |
CTD |
PMID:15652233 PMID:15670600 PMID:16479312 PMID:16837569 PMID:21430235 PMID:23564645 PMID:26750564 PMID:31299240 PMID:31830554 PMID:32003934 PMID:32259555 PMID:32305507 More...
|
|
NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
|
|
G |
SLCO1B3 |
solute carrier organic anion transporter family member 1B3 |
multiple interactions decreases activity decreases expression |
EXP |
Rifampin inhibits the reaction [SLCO1B3 protein results in increased import of cyanoginosin LR]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of estradiol-17 beta-glucuronide]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of fexofenadine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Ursodeoxycholic Acid metabolite] Rifampin results in decreased activity of SLCO1B3 protein Rifampin results in decreased expression of SLCO1B3 mRNA |
CTD |
PMID:17369605 PMID:18180276 PMID:21256917 PMID:21430235 PMID:27199754 PMID:31299240 PMID:31830554 PMID:32003934 PMID:32305507 More...
|
|
NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911
|
|
G |
SLCO2A1 |
solute carrier organic anion transporter family member 2A1 |
multiple interactions |
EXP |
Rifampin inhibits the reaction [decitabine results in increased expression of SLCO2A1 mRNA] |
CTD |
PMID:23137910 |
|
NCBI chr 3:133,932,701...134,029,925
Ensembl chr 3:133,932,701...134,052,184
|
|
G |
SLCO2B1 |
solute carrier organic anion transporter family member 2B1 |
multiple interactions increases expression |
EXP |
Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein] Rifampin results in increased expression of SLCO2B1 mRNA |
CTD |
PMID:21430235 PMID:27199754 |
|
NCBI chr11:75,151,107...75,206,549
Ensembl chr11:75,100,563...75,206,549
|
|
G |
SLCO4C1 |
solute carrier organic anion transporter family member 4C1 |
increases expression |
EXP |
Rifampin results in increased expression of SLCO4C1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 5:102,233,986...102,296,284
Ensembl chr 5:102,233,986...102,296,284
|
|
G |
SMAD9 |
SMAD family member 9 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr13:36,844,831...36,920,854
Ensembl chr13:36,844,831...36,920,765
|
|
G |
SNCA |
synuclein alpha |
multiple interactions increases sumoylation |
ISO |
Rifampin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SNCA protein modified form]; UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein] |
CTD |
PMID:17280646 PMID:28132806 |
|
NCBI chr 4:89,724,099...89,838,304
Ensembl chr 4:89,700,345...89,838,315
|
|
G |
SNORA71C |
small nucleolar RNA, H/ACA box 71C |
decreases expression |
EXP |
Rifampin results in decreased expression of SNORA71C mRNA |
CTD |
PMID:24552687 |
|
NCBI chr20:38,429,667...38,429,804
Ensembl chr20:38,429,670...38,429,803
|
|
G |
SOCS3 |
suppressor of cytokine signaling 3 |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:78,356,778...78,360,925
Ensembl chr17:78,356,778...78,360,077
|
|
G |
SORBS1 |
sorbin and SH3 domain containing 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of SORBS1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:95,311,773...95,561,371
Ensembl chr10:95,311,771...95,561,414
|
|
G |
SPTB |
spectrin beta, erythrocytic |
increases expression |
EXP |
Rifampin results in increased expression of SPTB mRNA |
CTD |
PMID:24552687 |
|
NCBI chr14:64,746,283...64,879,907
Ensembl chr14:64,746,283...64,879,907
|
|
G |
SQSTM1 |
sequestosome 1 |
increases expression |
EXP |
Rifampin results in increased expression of SQSTM1 protein |
CTD |
PMID:29908302 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
SRC |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
EXP |
[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:25069801 |
|
NCBI chr20:37,344,699...37,406,050
Ensembl chr20:37,344,685...37,406,050
|
|
G |
STAT5A |
signal transducer and activator of transcription 5A |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:42,287,547...42,311,943
Ensembl chr17:42,287,547...42,311,943
|
|
G |
STK39 |
serine/threonine kinase 39 |
increases expression |
EXP |
Rifampin results in increased expression of STK39 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:167,954,022...168,247,595
Ensembl chr 2:167,954,020...168,247,595
|
|
G |
SULT1E1 |
sulfotransferase family 1E member 1 |
multiple interactions |
EXP |
[NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer] |
CTD |
PMID:21764778 |
|
NCBI chr 4:69,821,122...69,860,145
Ensembl chr 4:69,841,212...69,860,145
|
|
G |
SULT2A1 |
sulfotransferase family 2A member 1 |
multiple interactions |
ISO |
[Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] |
CTD |
PMID:12370413 |
|
NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
|
|
G |
SUMO1 |
small ubiquitin like modifier 1 |
increases expression |
ISO |
Rifampin results in increased expression of SUMO1 protein |
CTD |
PMID:28132806 |
|
NCBI chr 2:202,206,171...202,238,597
Ensembl chr 2:202,206,182...202,238,599
|
|
G |
SUMO3 |
small ubiquitin like modifier 3 |
multiple interactions |
EXP |
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]] |
CTD |
PMID:26883953 |
|
NCBI chr21:44,805,617...44,818,062
Ensembl chr21:44,805,617...44,818,779
|
|
G |
SUN1 |
Sad1 and UNC84 domain containing 1 |
decreases expression |
EXP |
Rifampin results in decreased expression of SUN1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:815,557...874,934
Ensembl chr 7:816,615...896,435
|
|
G |
TBATA |
thymus, brain and testes associated |
decreases expression |
EXP |
Rifampin results in decreased expression of TBATA mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:70,771,238...70,785,377
Ensembl chr10:70,771,238...70,785,401
|
|
G |
TFEC |
transcription factor EC |
increases expression |
EXP |
Rifampin results in increased expression of TFEC mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:115,935,152...116,159,896
Ensembl chr 7:115,935,148...116,159,896
|
|
G |
THSD4 |
thrombospondin type 1 domain containing 4 |
increases expression |
EXP |
Rifampin results in increased expression of THSD4 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:71,096,894...71,783,383
Ensembl chr15:71,096,952...71,783,383
|
|
G |
TJP1 |
tight junction protein 1 |
affects localization decreases expression |
ISO |
Rifampin affects the localization of TJP1 protein Rifampin results in decreased expression of TJP1 mRNA |
CTD |
PMID:19577586 |
|
NCBI chr15:29,699,367...29,969,049
Ensembl chr15:29,699,367...29,968,915
|
|
G |
TJP2 |
tight junction protein 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of TJP2 mRNA |
CTD |
PMID:19577586 |
|
NCBI chr 9:69,121,264...69,255,208
Ensembl chr 9:69,121,264...69,274,615
|
|
G |
TLR1 |
toll like receptor 1 |
increases expression |
EXP |
Rifampin results in increased expression of TLR1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:38,787,569...38,805,644
Ensembl chr 4:38,790,677...38,856,817
|
|
G |
TMEM120B |
transmembrane protein 120B |
decreases expression |
EXP |
Rifampin results in decreased expression of TMEM120B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:121,712,752...121,782,068
Ensembl chr12:121,712,752...121,783,001
|
|
G |
TMEM145 |
transmembrane protein 145 |
increases expression |
EXP |
Rifampin results in increased expression of TMEM145 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr19:42,313,309...42,325,064
Ensembl chr19:42,313,309...42,325,064
|
|
G |
TMEM88 |
transmembrane protein 88 |
increases expression |
EXP |
Rifampin results in increased expression of TMEM88 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:7,855,066...7,856,099
Ensembl chr17:7,855,066...7,856,099
|
|
G |
TMPRSS2 |
transmembrane serine protease 2 |
increases expression |
EXP |
Rifampin results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr21:41,464,305...41,508,158
Ensembl chr21:41,464,300...41,531,116
|
|
G |
TNF |
tumor necrosis factor |
decreases expression |
EXP |
Rifampin results in decreased expression of TNF protein |
CTD |
PMID:21357946 |
|
NCBI chr 6:31,575,565...31,578,336
Ensembl chr 6:31,575,565...31,578,336
|
|
G |
TNFRSF10A |
TNF receptor superfamily member 10a |
multiple interactions |
ISO |
[Rifampin co-treated with Cobicistat] results in increased expression of TNFRSF10B mRNA |
CTD |
PMID:33629115 |
|
NCBI chr 8:23,190,452...23,225,102
Ensembl chr 8:23,190,452...23,225,102
|
|
G |
TNFSF10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475
|
|
G |
TRADD |
TNFRSF1A associated via death domain |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA |
CTD |
PMID:21224054 |
|
NCBI chr16:67,154,185...67,159,909
Ensembl chr16:67,154,185...67,159,909
|
|
G |
TRIM51 |
tripartite motif-containing 51 |
decreases expression |
EXP |
Rifampin results in decreased expression of TRIM51 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr11:55,883,297...55,891,810
Ensembl chr11:55,883,297...55,891,810
|
|
G |
TSKU |
tsukushi, small leucine rich proteoglycan |
increases expression |
EXP |
Rifampin results in increased expression of TSKU mRNA |
CTD |
PMID:24552687 PMID:27177772 |
|
NCBI chr11:76,782,280...76,798,144
Ensembl chr11:76,782,251...76,798,153
|
|
G |
UBE2I |
ubiquitin conjugating enzyme E2 I |
multiple interactions |
ISO |
UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein] |
CTD |
PMID:28132806 |
|
NCBI chr16:1,309,152...1,327,017
Ensembl chr16:1,308,880...1,327,018
|
|
G |
UGDH |
UDP-glucose 6-dehydrogenase |
multiple interactions increases expression |
EXP |
[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA Rifampin results in increased expression of UGDH mRNA |
CTD |
PMID:16292757 |
|
NCBI chr 4:39,498,755...39,527,439
Ensembl chr 4:39,498,755...39,528,311
|
|
G |
UGT1A1 |
UDP glucuronosyltransferase family 1 member A1 |
affects expression increases expression multiple interactions |
EXP |
Rifampin affects the expression of UGT1A1 mRNA Rifampin results in increased expression of UGT1A1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of UGT1A1 mRNA |
CTD |
PMID:15104253 PMID:15771232 PMID:15849716 PMID:18098064 PMID:22126990 PMID:24259679 PMID:29162470 PMID:31233785 More...
|
|
NCBI chr 2:233,760,270...233,773,300
Ensembl chr 2:233,760,270...233,773,300
|
|
G |
UGT1A3 |
UDP glucuronosyltransferase family 1 member A3 |
increases expression multiple interactions |
EXP |
Rifampin results in increased expression of UGT1A3 mRNA pimecrolimus inhibits the reaction [Rifampin results in increased expression of UGT1A3 mRNA] |
CTD |
PMID:25313206 PMID:29356861 |
|
NCBI chr 2:233,729,042...233,773,300
Ensembl chr 2:233,729,042...233,773,300
|
|
G |
UGT1A6 |
UDP glucuronosyltransferase family 1 member A6 |
increases expression |
EXP |
Rifampin results in increased expression of UGT1A6 mRNA |
CTD |
PMID:18094037 |
|
NCBI chr 2:233,691,702...233,773,300
Ensembl chr 2:233,691,607...233,773,300
|
|
G |
UGT1A9 |
UDP glucuronosyltransferase family 1 member A9 |
increases expression |
EXP |
Rifampin results in increased expression of UGT1A9 mRNA; Rifampin results in increased expression of UGT1A9 protein |
CTD |
PMID:25070100 |
|
NCBI chr 2:233,671,898...233,773,300
Ensembl chr 2:233,671,898...233,773,300
|
|
G |
UHRF2 |
ubiquitin like with PHD and ring finger domains 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of UHRF2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:6,413,199...6,507,054
Ensembl chr 9:6,413,151...6,507,054
|
|
G |
UNG |
uracil DNA glycosylase |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA |
CTD |
PMID:21224054 |
|
NCBI chr12:109,097,597...109,110,992
Ensembl chr12:109,097,597...109,110,992
|
|
G |
USP17L2 |
ubiquitin specific peptidase 17 like family member 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of USP17L2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:12,136,435...12,138,849
Ensembl chr 8:12,136,435...12,138,849
|
|
G |
VEGFA |
vascular endothelial growth factor A |
increases expression |
ISO |
Rifampin results in increased expression of VEGFA protein |
CTD |
PMID:25051504 |
|
NCBI chr 6:43,770,209...43,786,487
Ensembl chr 6:43,770,184...43,786,487
|
|
G |
VEGFD |
vascular endothelial growth factor D |
multiple interactions |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA |
CTD |
PMID:21127053 |
|
NCBI chr X:15,345,596...15,384,413
Ensembl chr X:15,345,596...15,384,413
|
|